

I N D E X

Volume Twenty-Three — January through December 1989

DICP, The Annals of Pharmacotherapy

JANUARY	Pages 1-104
FEBRUARY	Pages 105-92
MARCH	Pages 193-272
APRIL	Pages 273-352
MAY	Pages 353-440

JUNE	Pages 441-520
JULY/AUGUST	Pages 521-632
JULY/AUGUST	Pages S1-S31
Symposium	
SEPTEMBER	Pages 633-736

OCTOBER	Pages 737-832
OCTOBER	Pages S1-S46
Symposium	
NOVEMBER	Pages 833-950
DECEMBER	Pages 951-1064

SUBJECT INDEX

A

Absorption, clozapine (FF) 110; lorazepam (FF) 446; misoprostol (FF) 278; ofloxacin (FF) 840; propafenone, oral (FF) 197; trimethoprim/sulfamethoxazole, oral (A) 646
Acetabulol, cerebral hyperperfusion (A) 599
Acetaminophen, toxicity, delayed acetylcysteine absorption (L) 509
Acetazolamide, sleep apnea (DIAS) 308
Acetylcysteine, delayed absorption, acetaminophen toxicity (L) 509
N⁴-Acetylsulfamethoxazole, pharmacokinetics, renal dysfunction (A) 649
Acquired immunodeficiency syndrome, ganciclovir, cytomegalovirus (ID) 5; HIV-associated thrombocytopenia, management (TC) 157
Activated charcoal, see **Charcoal**, activated
Acylovir, compared with ganciclovir, cytomegalovirus (ID) 6
Addition, see **Dependence**
Additives, caffeine stability (SR) 466
Admixtures, see **Additives**
Adrenocorticotrophic hormone, see **Corticotropin**
Adriamycin, thrombotic microangiopathy (CR) 583
Adverse drug reactions, see **Drugs**, adverse reactions
Agranulocytosis, diclofenac (L) 507
AIDS, see **Acquired immunodeficiency syndrome**
Albumin, binding, meperidine (RPR) 568; utilization, cost (RPR) 214
Albuterol, compared with aminophylline, status asthmaticus (TC) 997; inhaler, compliance (RPR) 128
Allergies, antipyrine (CR) 38; cross sensitivity, phenytoin, carbamazepine (SR) 235; nitrofurantoin (L) 89; norfloxacin (L) 90; sulfites, with gentamicin (L) 1032
Alpha₂-acid glycoprotein, binding, meperidine (RPR) 568
Alprazolam, compared with clonidine, nicotine withdrawal (DIAS) 473; withdrawal, neonates, breast feeding (L) 614
Alzheimer's disease, ifenitamine hydrochloride (FF) 22
Ambulatory care, see also **Patients**, outpatients; education and practice (O) 520; prescribing, education-impact on (RPR) 770
American Association for World Health, see **Association News (NC)**
American Association of College of Pharmacy, see **Association News (NC)**
American Association of Pharmaceutical Scientists, see **Association News (NC)**
American College of Clinical Pharmacy, see also **Association News (NC)**; future objectives (ACCP) 488; historical perspective (ACCP) 487; pharmacotherapy definition (E) 73; specialty council appointments (E) 1031
American Foundation for Pharmaceutical Education, see **Association News (NC)**; Education and Research News (NC)
American Institute of the History of Pharmacy, see **Association News (NC)**
American Public Health Association, see **Association News (NC)**
American Society of Consultant Pharmacists, see **Association News (NC)**
Amino acids, branched chain, availability (A) 399, clinical trials (A) 400, (TC) 411, cost (A) 407, review (A) 399
Aminocaproic acid, hemodialysis (L) 922; seizures (SR) 780
Aminoglycosides, bacterial resistance (A) 556; clinical pharmacokinetics service (RPR) 33, (L) 622; compared with ofloxacin, bone infection (FF) 843; dosing (TC) 788; utilization, pneumonia (PEP) 164
Aminopenicillin, utilization, pneumonia (PEP) 164
Aminophylline, compared with albuterol, status asthmaticus (TC) 997; epinephrine, isoproterenol, status asthmaticus (TC) 996
Aminosalicylic acid, inflammatory bowel disease (A) 966
Amiodarone, AAPS, Condensed Scientific Fraud: Adopts Series of Policy Positions, 352; AAWH, World Health Day: April 7, 1989, 192;

Amitriptyline, bulimia (DIAS) 883; compared with bromocriptine, depression (DIAS) 601
Amoxapine, neuroleptic malignant syndrome (CR) 50, (L) 713
Amoxicillin, incompatible, ciprofloxacin (L) 91, pefloxacin (L) 91; with clavulanate potassium, incompatible, ciprofloxacin (L) 91, pefloxacin (L) 91
Amphotericin B, interaction, flucytosine (SR) 672
Ampicillin, sodium, bacteria, iv solution (RPR) 210
Ampirone, congestive heart failure, home infusion (SR) 59
Analgia, lidocaine, intravenous (DIAS) 602; patient-controlled, review (A) 899
Anaphylaxis, cyclophosphamide (L) 88; methotrexate, prevention (L) 1032; streptokinase (CR) 869, (CR) 984
Anemia, aplastic, locaine (L) 90; hemolytic, phenazopyridine, trimethoprim/sulfamethoxazole (CR) 140
Anesthesia, induction, butorphanol/diazepam compared with thiopental (RPR) 659; intravenous regional, 2-chloroprocaine (L) 614
Anesthetics, topical, organic nitrate-induced methemoglobinemia (A) 284
Angina, nifedipine, sublingual, compared with nitroglycerin (RPR) 562
Anion-exchange resins, with vancomycin, pseudomembranous colitis (DIAS) 70
Anions, organic, drug interactions (A) 119
An Opinion, Carson, Stanley W., Bupropion, Is It Here to Stay?, 704; Carter, Barry L., Are You an Academician?, 920; Coyle, James D., Schaaf, Stephen F., An Interim Perspective on the Removal of Encainide and Flecainide from the Cardiac Arrhythmia Suppression Trial, 478; Halperin, Jerome A., Potassium Iodide as a Thyroid Blocker—Three Mile Island to Today, 422; Jordan, M. Colin, Ganciclovir for Treatment of Cytomegalovirus Disease, 85; Levy, Richard A., Smith, Dorothy L., Clinical Differences Among Nonsteroidal Antiinflammatory Drugs: Implications for Therapeutic Substitution in Ambulatory Patients, 76; Radandt, Joan M., Tartaglione, Teresa A., The Role of Aerosolized Pentamidine in Management of HIV-Related Pneumocystis carinii Pulmonary Infections, 806; Welty, Timothy E., The Need for a Spiritual Dimension in Pharmacy Education, 373
Antacids, aspiration pneumonia (CS) 205
Antiaerobic agents, utilization, pneumonia (PEP) 164
Antibiotics, bacterial resistance (A) 556; inflammatory bowel disease (A) 969; selection S7 (J/A), microbiology, pharmacokinetics S16 (J/A); utilization, monitoring S15 (J/A), national review (PEP) 162
Antidepressants, see **elderly (G)** 611
Antidiarrheal agents, inflammatory bowel disease (A) 969
Antihypertensive agents, see **Hypertensive agents**
Antinflammatory agents, nonsteroidal, ketoprofen, FDA-approved indications (L) 432; nephrotoxicity, lack, elderly (E) 74; therapeutic substitution (O) 76
Antimicrobial agents, see **Antibiotics**
Antineoplastic agents, thrombotic microangiopathy (CR) 582
Antipsychotics, pregnancy (DIAS) 598
Antipyrine, allergic reaction (CR) 38
Anxiolytic agents, see **elderly (G)** 611
Apnea, sleep, acetazolamide (DIAS) 310, bromocriptine (DIAS) 311, clomipramine (DIAS) 310, imipramine (DIAS) 310, medroxyprogesterone acetate (DIAS) 309, naloxone (DIAS) 309, nomifensine (DIAS) 310, propylthiouracil (DIAS) 308, trazodone (DIAS) 311, tryptophan (DIAS) 311
Arrhythmias, clonidine (SR) 465; ventricular, encainide, flecainide, use restriction (O) 478, propafenone, review (FF) 198; steroids, cortico-, review (DIR) 1019; verapamil, continuous infusion (DIAS) 1005
Aspirin, interaction, atenolol, captopril, chlorpropamide, furosemide, isosorbide dinitrate, nadolol, nitroglycerin, prednisone, propranolol, tolazamide (L) 340; nephrotoxicity, lack, elderly (E) 74
Assays, see **Therapeutic monitoring**
Assessment, functional, geriatrics (G) 847
Association News (NC), AACP, Faculty Salary Survey, 520; AAPS, Condensed Scientific Fraud: Adopts Series of Policy Positions, 352; AAWH, World Health Day: April 7, 1989, 192;

ACCP, Cardiovascular Research Fellowship Established, 440, Research Institute Announces 1989 Award Recipients, 440, Residencies and Fellowships Directory, 104, Tenth Annual Meeting Highlights, 735; AFPE, Fellowships, 352; AIHP, Applications Invited for Grants-in-Aid to Graduate Students and Teachers, 949; APHA, Drug Policy and Pharmaceutical Services Committee, 1054, Policy Statements, 1054; ASCP, Executive Residency Program, 271, Invites Nominations for Archambault and Berman Awards, 271; IPSF, Meets in Philadelphia, 192; JCPP, Welcomes ACCP, 632; Pharmacy Council on Cholesterol established, 352; Phi Delta Chi Fraternity, Prescott Leadership Award Seeks Applicants, 192
Asenazole, compared with lorazepam (FF) 447
Asthma, see also **Status asthmaticus**; beclomethasone dipropionate (DIAS) 597
Atenolol, cerebral ischemia (SR) 238; compared with propranolol, migraine (DIAS) 248; interaction, aspirin (L) 340
Azathioprine, inflammatory bowel disease (A) 968

B

Bacillus cereus, survival, iv solutions (RPR) 210
Bacillus subtilis, survival, iv solutions (RPR) 210
Bacteria, survival, iv solutions (RPR) 210
Beclomethasone dipropionate, chronic asthma (DIAS) 597
Benzodiazepine, withdrawal, midazolam (SR) 151
Benzylpenicillin potassium, bacteria, iv solution (RPR) 210
Beta-blockers, see **Sympatholytic agents**
Beta-lactams, bacterial resistance (A) 556
Betamethasone valerate, inflammatory bowel disease (A) 968
Beta₂-Microglobulin, excretion, cystic fibrosis (PED) 1013
Binding, meperidine, alpha₂-acid glycoprotein, albumin (RPR) 568; protein, misoprostol (FF) 278, trimethoprim/sulfamethoxazole (A) 647, review S28 (J/A)
Bioavailability, see **Drugs**, availability
Bioelectrical impedance, review (A) 548
Bioequivalency, see **Equivalency**
Bleomycin, thrombotic microangiopathy (CR) 583
Blood levels, see **Therapeutic monitoring**
Board of Pharmaceutical Specialties, approval, nuclear pharmacists (NC) 949; history (E) 909; pharmacotherapy petition (E) 73, (E) 909; Specialty Council on Pharmacotherapy meeting (NC) 736
Book Reviews, AARP Pharmacy Service Prescription Drug Handbook (N.J. Olins), 180; Analytical Aspects of Drug Testing (D.G. Deutsch), 929; Applied Therapeutics: The Clinical Use of Drugs, 4th Edition (L.Y. Young, M.A. Koda-Kimble), 262; Atherosclerosis Reviews, Volume 18: Hypercholesterolemia Clinical and Therapeutic Implications (J. Stokes III, M. Mancini), 263; Boyd's Introduction to the Study of Disease, 10th Edition (H. Sheldon), 95; British Pharmacopoeia 1988, 433; Catalog of Teratogenic Agents, 6th Edition (T.H. Shepard), 1038; Clinical Pharmacokinetics: Concepts and Applications, 2nd Edition (M. Rowland, T.N. Tozer), 263; Clinical Pharmacy and Therapeutics, 4th Edition (E.T. Herfindal, D.R. Gourley, L.L. Hart), 433; Drug-Induced Ocular Side Effects and Drug Interactions, Third Edition (F.T. Fraunfelder), 1038; Drug Interactions: Sixth Edition (P.D. Harsten, J.R. Horn), 181; Drugs and the Elderly: Clinical, Social, and Policy Perspectives (H.L. Lipton, P.R. Lee), 181; Important Advances in Oncology 1989 (V.T. DeVita, S. Hellman, A. Rosenberg), 1037; Medicine for the Practicing Physician, 2nd Edition (J.W. Hurst), 96; Pharmacotherapy: A Pathophysiologic Approach (J.T. DiPiro, R.L. Talbert, P.E. Hayes, G.C. Yee, L.M. Posey), 95; Physician's 1989 Drug Handbook, 117; Psychoactive Drugs: Improving Prescribing Practices (H. Ghodse, I. Khan), 817; Teratogens—Chemicals Which Cause Birth Defects (V.K. Meyers), 96; Therapeutic Pharmacology (G.D. Appelt, J.M. Appelt), 817; USP DI, 9th Edition, Volume III: Approved Drug Products and Legal Requirements, 1037
Books, text, required, clinical pharmacology education (L) 430
Books Received, see also **Journals Received**, **Software Received**; 97, 182, 264, 342, 433, 720, 929, 1039

Breast milk, see Lactation
Bromocriptine, compared with amitriptyline, depression (DIAS) 600; sleep apnea (DIAS) 311
Bulimia, amitriptyline, desipramine, imipramine, mianserin, phenelzine (DIAS) 882
Bulimins, see **Neurexins**
Bupropion, FDA-approved labeling (O) 704; seizure incidence (O) 704
Burns, metocurine iodide, pancuronium bromide, tubocurarine chloride, dosage (DIAS) 1007
Bupropion, abuse (DIAS) 1035
Butorphanol, with diazepam, compared with thiopental, anesthesia induction (RPR) 659

C

Caffeine, interaction, lack, ofloxacin (FF) 843; stability, admixtures, parenteral nutrition (SR) 466, (L) 928; syringes (L) 1035
Calcium antagonists, combination therapy, ischemic heart disease (DIAS) 245; review (DSP) 538
Calcium channel blockers, see **Calcium antagonists**
Campbell, R. Keith, Outstanding Health Professional Educator in the Field of Diabetes, American Diabetes Association (NC) 832
Captopril, bulous pemphigoid (SR) 63; cerebral hyperperfusion (A) 959; interaction, aspirin (L) 340
Carbamazepine, clearance, hemodialysis (CR) 137; cross-sensitivity, phenytoin (SR) 235; hypocalcemia (L) 1034; interaction, erythromycin (SR) 878
Cardoni, Alex A., representative, Mental Health Catchment Area Council No. 15, Connecticut Department of Mental Health (NC) 192
Carprofen, nephrotoxicity, lack, elderly (E) 74
Case Reports, see **Pharmacotherapy Case Reports**
Cations, organic, drug interactions (A) 119
Cefactor, theophylline toxicity (L) 339
Cefamandole, compared with ciprofloxacin, cost (L) 92; dosing (S) 118 (JA)
Cefazolin, dosing (S) 110, (S) 117 (JA)
Cefonicid, compared with cefoxitin, prophylaxis (RPR) 655; utilization (SR) 155
Cefotaxime, dosing (S) 111 (JA)
Cefotetan, compared with cefoxitin, formulary conversion (PEC) 1024; dosing (S) 110, (S) 118 (JA)
Cefoxitin, compared with cefonicid, prophylaxis (RPR) 655; compared with cefotetan, formulary conversion (PEC) 1024; dosing (S) 118 (JA)
Cefprozime, stability, iv solutions (L) 615
Ceftriaxone, dosing (S) 111, (S) 119 (JA)
Cefuroxime sodium, bacteria, iv solution (RPR) 210
Cephalosporins, adverse reactions (S) 9 (JA); bacterial resistance (A) 556; formulary choice (S) 9 (JA); pharmacology (S) 9 (JA); utilization, pneumonia (PEP) 164
Cephalexin, dosing (S) 117 (JA)
Charcoal, activated, magnesium citrate with clidinium bromide, excretion (RPR) 26
Chloramphenicol, bacterial resistance (A) 556
Chloridiazepoxide, use, elderly (G) 610
2-Chloroprocaine, intravenous regional anesthesia (L) 614
Chlorpheniramine, compared with loratadine (FF) 447
Chlorpromazine, compared with clozapine, schizophrenia (FF) 111; sudden death (L) 510
Chlorpromazine, interaction, aspirin (L) 340
Cholera, vaccine (NC) 191
Cholestyramine, inflammatory bowel disease (A) 970; pseudomembranous colitis (DIAS) 70
Chromatography, high-performance liquid, compared with EMIT, quinidine (TM) 999
Cimetidine, aspiration pneumonia (CC) 203; compared with famotidine, acid-suppression, critically ill patients (S) 36 (Oct); theophylline pharmacokinetics (S) 18 (Oct); compared with misoprostol (FF) 279; compared with ranitidine, drug utilization evaluation (L) 82; hydrochloride, with copper sulfate, stability, TPN (L) 429; interaction, diazepam, phenytoin (S) 19 (Oct); procainamide, warfarin (S) 20 (Oct); interaction, lack, procainamide (FF) 198; interaction, possible, warfarin (TC) 675; procainamide (A) 120; intravenous, continuous infusion, critically ill patients (S) 40 (Oct); malignant melanoma (DIAS) 689; pharmacokinetics (S) 13 (Oct); thrombocytopenia (L) 177
Ciprofloxacin, compared with cefamandole, cost (L) 92, ofloxacin, respiratory infection (FF) 841; incompatible, amoxicillin (L) 91, amoxicillin/clavulanic acid (L) 91, floxacillin (L) 91; iv administration, MIC/MBC (RPR) 456
Cirrhosis, liver, colchicine (DIAS) 388
Cisplatin, thrombotic microangiopathy (CR) 583
Clavulanic acid, with amoxicillin, incompatible, ciprofloxacin (L) 91, pefloxacin (L) 91
Clearance, see **Excretion**
Clemastine, compared with loratadine (FF) 447
Clidinium bromide, with magnesium citrate, activated charcoal excretion (RPR) 26
Clindamycin, dosing, costs (RPR) 980
Clinical pharmacy, see **Pharmacy, clinical**
Clinical Pharmacy Case Reports, see **Pharmacotherapy Case Reports**
Clinical Statistics, Comparison of Linear Regression Methods When Both Variables Contain Error: Relation to Clinical Studies, 891
Clinical studies, amino acids, branched chain (A) 400; clozapine (FF) 110; cocaine (A) 640; economic research (PEC) 694; erythropoietin (FF) 530; famotidine (S) 117 (Oct); ganciclovir (ID) 5; ifenbuterol hydrochloride (FF) 20; loratadine (FF) 447; milrinone (FF) 359; misoprostol (FF) 278; nifedipine (FF) 452; ofloxacin (FF) 841; propafenone (FF) 199; propofol (FF) 746
Clomipramine, sleep apnea (DIAS) 310; treatment (ND) (NC) 104
Clonidine, cardiac dysrhythmia (SR) 465; compared with alprazolam, nicotine withdrawal (DIAS) 473; compared with nifedipine, cerebral hyperperfusion (A) 960; inflammatory bowel disease (A) 969; nicotine withdrawal (L) 1035; orthostatic hypotension (G) 753
Clophenoxol, compared with clozapine, schizophrenia (FF) 111
Clozapate, use, elderly (G) 610

Clostridium difficile, pseudomembranous colitis (DIAS) 70
Clozapine, adverse reactions (FF) 112; compared with chlorpromazine, clophenoxol, haloperidol, trifluoperazine, schizophrenia (FF) 111; compared with perphenazine, organic psychosis (FF) 111; pharmacokinetics (FF) 110; pharmacology (FF) 110; review (FF) 109
Cocaine, pharmacology (A) 639; teratogenicity, review (A) 639
Codeine, dependence (DIAS) 475
Colchicine, liver cirrhosis (DIAS) 388
Colistipol, with vancomycin, pseudomembranous colitis (DIAS) 70
Colitis, pseudomembranous, cholestyramine (DIAS) 70, vancomycin, with colistipol (DIAS) 70; ulcerative, review (A) 963
Compatibilities, see **Incompatibilities**
Compliance, metered-dose inhalers (RPR) 128; rifampin, thrombocytopenia (CR) 382
Concentration, see **Therapeutic monitoring**
Congestive heart failure, see **Heart failure, congestive**
Consumers, pharmacist consultation (RPR) 218
Contact lens, damage, ribavirin (L) 428
Contraceptives, oral, hypercarotenemia (L) 811, triphasic, idiopathic thrombocytopenia (CR) 773
Contrast media, see **Radiographic agents**
Convulsions, see **Seizures**
Copper sulfate, with cimetidine hydrochloride, TPN, stability (L) 429
Corrections, see **Letters**
Corticosteroids, see **Steroids, corticosteroids**
Corticosteroid, inflammatory bowel disease (A) 968
Costs, see **Pharmacoeconomics**
Co-trimoxazole, see **Trimethoprim**, with **sulfamethoxazole**; **Sulfamethoxazole**, with **trimethoprim**
Creatinine, clearance, Cushing's syndrome (RPR) 974; cystic fibrosis (PED) 1013
Critical Care Therapeutics, Drug-Induced Metabolic Disorders and Parenteral Nutrition in the Intensive Care Unit: A Pharmaceutical and Metabolic Perspective, 363; Intraoperative Complications in Patients Receiving Anesthetics: Characteristics and Risk Factors, 757; Physiologic Implications of Mechanical Ventilation on Pharmacokinetics, 316; Reducing the Risk of Aspiration Pneumonitis, 203
Crohn disease, review (A) 963
Cross sensitivity, see **Allergies**
Curriculum, see also, **Education**; changes (E) 250, (ET) 912, (O) 920
Cushing's syndrome, creatinine clearance (RPR) 974
Cyclophosphamide, anaphylaxis (L) 88; erythrocytopenia (CR) 776; thrombotic microangiopathy (CR) 583; with mesna, immunosuppression (DIAS) 798
Cyclosporin A, see **Cyclosporine**
Cyclosporine, diabetes mellitus (DIAS) 307; inflammatory bowel disease (A) 969; sampling, silicone central venous lines (RPR) 300
Cystic fibrosis, excretion, beta₂-microglobulin, creatinine (PED) 1013
Cystitis, dinoprost, dinoprostone (DIAS) 885
Cytarabine, treatment (ND) (NC) 104
Cytomegalovirus, ganciclovir (ID) 5, (O) 85; review (ID) 5
Cytomegalovirus immune globulin, treatment (ND) (NC) 104

D

Dacarbazine, thrombotic microangiopathy (CR) 583
Dactinomycin, thrombotic microangiopathy (CR) 583
Danazol, HIV-associated thrombocytopenia (TC) 158
Degrees, see **Education**
Delusions, parositis, pimozide (CR) 304
Dental caries, xylitol (DIAS) 691
Dependence, cocaine, teratogenicity (A) 639; codeine (DIAS) 475; diazepam, panic attacks, depression (SR) 989; nicotine, clonidine (DIAS) 473, (L) 1035
Depression, bromocriptine (DIAS) 600; diazepam, dependence (SR) 989
Desipramine, bulimia (DIAS) 883
Diabetes mellitus, cyclosporine (DIAS) 307; mortality (NC) 949; neuropathy, fluoxetine (CR) 572; nifedipine, increased insulin requirement (SR) 236
Dialysis, hemo-, aminocaproic acid (L) 922; carbamazepine (CR) 137; erythropoietin, human recombinant, review (FF) 528; trimethoprim/sulfamethoxazole (A) 649; peritoneal, trimethoprim/sulfamethoxazole (A) 649
Diarrhea, travelers', self-medication (PEP) 800
Diagnosis-related groups, see also, **Pharmacoeconomics**; antibiotics (S) 13 (JA)
DIAS Rounds, Anion-Exchange Resins and Oral Vancomycin in Pseudomembranous Colitis, 70; Antidepressants Used in Bulimia, 882; Beclomethasone Dipropionate in Chronic Asthma, 597; Beta-Blocking Agents for Migraine, 248; Bromocriptine in Treatment of Depression, 600; Calcium-Channel Blockers in Ischemic Heart Disease, 245; Cimetidine in Malignant Melanoma, 689; Clonidine in Nicotine Withdrawal, 473; Codeine Addiction, 475; Colchicine in Liver Cirrhosis, 388; Continuous Verapamil Infusion, 1005; Cyclosporine and Recent-Onset Diabetes Mellitus, 307; Dinoprost in Hemorrhagic Cystitis, 885; Drug Treatment for Sleep Apnea, 308; Effect of Mesna on Cyclophosphamide, 798; Gonadotropin-Releasing Hormone in Infertility, 246; IV Lidocaine as an Analgesic, 602; Neuromuscular Blocking Agents in Burn Patients, 1006; Pediatric Bowel Evacuation with a Polyethylene Glycol and Iso-osmolar Electrolyte Solution, 1008; Noxonyl 9 in Herpes, 602; Phenothiazines and Sudden Infant Death Syndrome, 795; Phenytoin-Enteral Feeding Interaction, 796; Prazosin in Benign Prostatic Hyperplasia, 474; Prevention of Heterotopic Ossification, 71; Probuloc in Hypercholesterolemia, 880; TMP/SMX in Renally Impaired Patients with *P. carinii* Pneumonia, 687; Tocainide in Myotonic Dystrophy, 69; Treatment of Doxorubicin Extravasations, 386; Treatment of Psychosis in Pregnancy, 598; Xylitol for Prevention of Dental Caries, 691
Diazepam, dependence, panic attacks, depression (SR) 989; interaction, cimetidine, famotidine (S) 119 (Oct); use, elderly (G) 610; with butorphanol, compared with thiopental, anesthesia induction (RPR) 659
Diclofenac, agranulocytosis (L) 507

DICP, title alteration (E) 73
Digoxin, absorption, malabsorption syndrome (RPR) 764; concentrations, pharmacokinetics (L) 717, toxicity (L) 93; interaction, erythromycin (CR) 668, propafenone (FF) 198; interaction, lack, milrinone (FF) 360
Digoxin-like immunoreactive substance, assay interference (L) 93; toxicity (L) 93
Dihydralazine, cerebral hypoperfusion (A) 959
Dihydroergotamine, orthostatic hypotension (G) 754
Diltiazem, acute myocardial infarction, review (DSP) 544; with nifedipine, ischemic heart disease (DIAS) 245
Dinoprost, hemorrhagic cystitis (DIAS) 885
Dinoprostone, hemorrhagic cystitis (DIAS) 885
Diphenhydramine, utilization, nursing homes (L) 178
Dipyridamol, myocardial infarction (CR) 665
Sodium etidronate, heterotopic ossification (DIAS) 71; Paget's disease (DIAS) 71
Disopyramide, compared with propafenone (FF) 199; concentration, breast milk (SR) 56, serum (SR) 56
Disulfiram, hepatitis (CR) 872
Dobutamine, compared with milrinone (FF) 359
Doluisio, James T., 1989 Rho Chi Lecture Award recipient (NC) 352
Dormiprone, orthostatic hypotension (G) 754
Dosage, aminoglycosides, alternative strategy (TC) 788; cephalosporins, comparison (S) 110 (JA); clindamycin, costs (RPR) 980; imipramine, prediction techniques (TM) 389; lithium, prediction (RPR) 372; neuromuscular blocking agents, burns (DIAS) 1006; rate, pharmacokinetics (TM) 468; theophylline, guidelines (L) 713; trimethoprim/sulfamethoxazole, renal dysfunction (A) 652; vancomycin, Bayesian method (RPR) 294, methodology (RPR) 123, (L) 618
Dosage form, aerosol, pentamidine, *Pneumocystis carinii* pneumonia (L) 718; intravenous, ciprofloxacin (RPR) 456; erythromycin in lactobionate (CR) 40, histamine₂-receptor antagonists (S) 40 (Oct), heparin lock vs iv line (S) 626 (Oct), isoniazid, rifampin (CR) 48, lidocaine, analgesia (DIAS) 602, verapamil, continuous infusion (DIAS) 1005; regional anesthesia, 2-chloroprocaine (L) 614; rectal, phenobarbital sodium, parenteral solution (RPR) 565; sublingual, nifedipine, compared with nitroglycerin, angina (RPR) 562; topical, promethazine (L) 89
Doxorubicin, extravasation, therapy (DIAS) 386, (L) 928
Doxycycline, compared with ofloxacin, respiratory infection (FF) 841, sexually transmitted disease (FF) 842
Drug abuse, buspirone (L) 1035; cocaine, teratogenicity (A) 639; codeine (DIAS) 475; diazepam (SR) 989
Drug administration, functional ability, geriatrics (G) 171
Drug evaluations, see **Formulary Forum**; **Investigational Drug Information**
Drug information, bulletins, effectiveness (R) 330; elderly ambulatory patients, auxiliary labeling (G) 324; foreign drug identification (R) 501, (L) 815, (L) 1036; practice needs (L) 260; verbal, community pharmacists (RPR) 862
Drug Information Analysis Service, see **DIAS Rounds**
Drug Intelligence and Clinical Pharmacy, see **DICP**
Drug interactions, amphotericin B-flucytosine (SR) 672
aspirin-atenolol (L) 340
aspirin-captopril (L) 340
aspirin-chlorpromazine (L) 340
aspirin-furosemide (L) 340
aspirin-isosorbide dinitrate (L) 340
aspirin-nadolol (L) 340
aspirin-nitroglycerin (L) 340
aspirin-prednisone (L) 340
aspirin-propranolol (L) 340
aspirin-solazamide (L) 340
atenolol-aspirin (L) 340
caffeine-ofloxacin, lack (FF) 843
captopril-aspirin (L) 340
carbamazepine-erythromycin (SR) 878
chlorpromazine-aspirin (L) 340
cimetidine-procainamide (A) 120
cimetidine-propafenone (FF) 198
digoxin-erythromycin (CR) 668
digoxin-milrinone, lack (FF) 360
digoxin-propafenone (FF) 198
enteral feeding-phenytoin (DIAS) 796
erythromycin-carbamazepine (SR) 878
erythromycin-digoxin (CR) 668
flucytosine-amphotericin B (SR) 672
food-nifedipine, sustained-release (RPR) 662
furosemide-aspirin (L) 340
isoniazid-theophylline (CR) 143
isosorbide dinitrate-aspirin (L) 340
milrinone-digoxin, lack (FF) 360
nadolol-aspirin (L) 340
nifedipine, sustained-release-food (RPR) 662
nitroglycerin-aspirin (L) 340
ofloxacin-caffeine, lack (FF) 843
ofloxacin-Maalox (FF) 843
ofloxacin-theophylline, lack (FF) 843
phenytoin-enteral feeding (DIAS) 796
prednisone-aspirin (L) 340
procainamide-ranitidine (A) 120
procainamide-cimetidine (A) 120
procainamide-trimethoprim (A) 121
propafenone-cimetidine, lack (FF) 198
propafenone-digoxin (FF) 198
propafenone-warfarin (FF) 198
propranolol-aspirin (L) 340
pyrantel pamoate-theophylline (L) 258
ranitidine-procainamide (A) 120
renal transport mechanisms (A) 116
sulfamethoxazole, with **trimethoprim-warfarin** (L) 619
theophylline-isoniazid (CR) 143
theophylline-ofloxacin, lack (FF) 843
theophylline-pyranol pamoate (L) 258
tolazamide-aspirin (L) 340
trimethoprim, with **sulfamethoxazole-warfarin** (L) 619
trimethoprim-procainamide (A) 121
warfarin-propafenone (FF) 198
warfarin-trimethoprim/sulfamethoxazole (L) 619
Drug Interactions and Reactions Update, Severe Cardiovascular Adverse Effects in Association with Acute, High-Dose Corticosteroid Administration, 1019

Drug Selection Perspectives, Calcium-Channel Blockers in

Acute Myocardial Infarction (MI) 538

Drug therapy monitoring, see Therapeutic monitoring

Drug utilization, see also Pharmacoeconomics, albumin

(RPR) 214; antibiotics, bacterial pneumonia, national review

(PEP) 162, hospital 513 (JA); cefonicid (SR) 154; diphenhydramine, nursing homes (L) 178; psychotropics, elderly (G) 610; temazepam, nursing homes (L) 178; triazolam, long-term, elderly (RPR) 290; zidovudine (PEP) 698

Drug utilization evaluation, cimetidine compared with ranitidine (L) 812

Drugs, adverse reactions, aminocaproic acid, seizures (RPR) 780;

amoxapine, neuroleptic malignant syndrome (CR) 50, (L) 713;

antipyrene, allergy (CR) 38; atenolol, cerebral ischemia (SR) 238;

carbamazepine, hypocalcemia (L) 1034; cimetidine, thrombocytopenia (L) 177; clonidine, cardiac dysrhythmia

(SR) 465; clozapine, review (FF) 112; contraceptives, oral, hypercarotenemia (L) 811, triphasic, idiopathic thrombocytopenic purpura (CR) 773; contrast media, review (L) 925; cyclophosphamide, anaphylaxis (L) 88, erythrocytopenia (CR) 776; d-clofenac, agranulocytosis (L) 507; dipyridamol, myocardial infarction (CR) 665; disulfiram, hepatitis (CR) 872; enalapril, cerebral ischemia (SR) 238; encainide, hyperglycemia (L) 711;

erythromycin lactobionate, nausea, vomiting (CR) 40; erythropoietin, recombinant human, review (FF) 528; erythronol, neuroleptic malignant syndrome (L) 811; etoposide, acute hypotension (SR) 876, loss of consciousness (L) 177; famotidine, thrombocytopenia (L) 507; fluoxetine, seizures (L) 428; ganciclovir, neutropenia, review (ID) 9; gentamicin, with sulfites, sensitivity (L) 1032; hydrocortisone, folliculitis (L) 1033; ibuprofen, aseptic meningitis (L) 712; lorazepam, review (FF) 448; methazolamide, leukopenia, thrombocytopenia (SR) 58; methotrexate, prevention (L) 1032; metolazone, pancreatitis (L) 711; midazolam, hostility, hallucinations (CR) 671; mirtazapine, review (FF) 359; misoprostol, review (FF) 280; muniton CD3, aseptic meningitis (L) 257, (L) 716; nifedipine, diabetogenic effect (SR) 236, nonthrombocytopenic purpura (L) 88; nifedipine, review (FF) 448; nitrofurantoin, allergy (L) 89; nortriptyline, allergy (L) 89; NSAID, renal dysfunction (E) 74; ofloxacin, review (FF) 843; OKT3, aseptic meningitis (L) 257; Pergoecic, esophageal injury (CR) 227; phenazopyridine, with trimethoprim/sulfamethoxazole, hemolytic anemia (CR) 140; phenytoin, hepatotoxicity (A) 13; propafenone, review (FF) 200; propofol, review (FF) 147; pyrimethamine, with sulfadoxine, toxic epidermal necrolysis (NC) 192; ranitidine, chest pain (CR) 224, thrombocytopenia (L) 508; rifampin, thrombocytopenia (CR) 82; steroids, corticosteroid, cardiovascular effects, review (DIR) 1019; streptokinase, anaphylaxis (CR) 869, (CR) 984; sulfadoxine, with pyrimethamine, toxic epidermal necrolysis (NC) 192; sulfites, sensitivity, with gentamicin (L) 1032; tetracycline, leukopenia (CR) 45; thioridazine, neuroleptic malignant syndrome (L) 712; tocinide, aplastic anemia (L) 90; trimethoprim/sulfamethoxazole, with phenazopyridine, hemolytic anemia (CR) 140; verapamil, Stevens-Johnson syndrome (SR) 987

Drugs, availability, cocaine (A) 639; ganciclovir (ID) 7; mirtazapine (FF) 358; nifedipine sustained-release (RPR) 662; nifedipine (FF) 452; nonprescription, approval (E) 606; phenobarbital sodium, rectally administered (RPR) 565; praziquantel (RPR) 29; propafenone (FF) 197; trimethoprim/sulfamethoxazole (A) 646

Drugs, body distribution, ifenprodil (FF) 20; lorazepam (FF) 446; ofloxacin (FF) 940; propafenone (FF) 198; propofol (FF) 745

Drugs, generic, FDA testing (NC) 832; prescribing, physician education (RPR) 770

E

Economics, see Pharmacoeconomics

Editorials, see also An Oculist; Blum, Robert A.; Watson, William A.; Aagaard and Nonsteroidal Antiinflammatory Drug-Induced Renal Dysfunction, 74; McLeod, Donald C., Biotechnology: Product Development and Evolving Patent Law, 605, Nonprescription Drug Approval: Therapeutic Strategy or Marketing Decision?, 606, Pharmacotherapy: Part I. A New Pharmacy Specialty, 909, Pharmacotherapy: Part II. Administering the Certification Process, 1031; Nahata, Milap C., Issues Facing Clinical Pharmacy Education for Undergraduate Students, 250, Publishing by Pharmacists, 809; Rapp, Robert P., Parental Nutrition: 1989 and Beyond, 703; Whitney, Harvey A.K., Jr., The Annals of Pharmacotherapy—More than a Face Lift, 73

Education, see also Curriculum; pharmaceutical, ACCP Directory of Residency and Fellowship Programs (NC) 104, attitude (L) 259, clinical, academic appointment (O) 920, ethics (SR) 590, experiential (L) 715, nurturance (L) 926, postgraduate training (L) 342, publishing internship (L) 178, spiritual dimension (O) 337, textbook insufficiency (L) 1031, textbooks required (L) 430, two levels (L) 259, undergraduate (E) 250, Whispering Pines Conference (ET) 912; physician, prescribing (RPR) 770

Education and Research News (NC), AFPE Board of Grants Awards, 520; AFPE Scholarships and Fellowships Available, 1054; Council on CPE Research Grants: 1989-90, 949; Non-traditional Doctor of Pharmacy Degree, 440

Education and Training, Clinical Pharmacy Education in New England: A Report of the Whispering Pines Conference, 912

Educational Events, 101, 188, 269, 350, 439, 514, 526, 634, 831, 950, 1052

Edwards, David J., pharmacy's best teachers, American Association of Colleges of Pharmacy (NC) 832

Enalapril, cerebral hypoperfusion (A) 959, ischemia (SR) 238

Encainide, arrhythmias (NC) 736; cardiac arrest rate (O) 478; hyperglycemia (L) 711

Enoxacin, compared with ofloxacin, respiratory infection (FF) 841

Epidemiology, estrogen replacement therapy (RPR) 977; inflammatory bowel disease (A) 963

Epinephrine, compared with amphetamine, isoproterenol, status asthmaticus (TC) 996

Equipment, central venous lines, silicone, cyclosporine sam-

pling (RPR) 300; dual-lumen peripheral iv catheter, tobramycin (RPR) 460; infusion pump, malfunctions, osteomyelitis (CR) 379; patient-controlled analgesia (A) 901; metered-dose inhalers (L) 815, extender device adaptability (L) 341; syringes, glass, plastic, caffeine stability (L) 1075, polyvinyl chloride, famotidine stability (SR) 588

Equivalency, leucovorin calcium (SR) 153; therapeutic, NSAID (O) 76

Erythrodysaesthesia, cyclophosphamide (CR) 776

Erythromycin, interaction, carbamazepine (SR) 878, digoxin (CR) 668; lactobionate, nausea, vomiting (CR) 40

Erythropoietin, recombinant human, adverse reactions (FF) 531; patent litigation (E) 605; pharmacokinetics (FF) 528; review (FF) 528

Esophagus, injury, Pergoecic (CR) 227

Estrogen, neuroleptic malignant syndrome (L) 811; replacement therapy, prescribing (RPR) 977

Ethics, pharmaceutical industry, gifts (IR) 175; pharmacy students (SR) 590

Ethylene glycol, toxicity, osmolality formula (L) 432

Etoposide, acute hypotension (SR) 876; loss of consciousness (L) 177

Europe, fish oil, registration (L) 92

Excretion, activated charcoal, magnesium citrate with clindamycin bromide (RPR) 26; carbamazepine, hemodialysis (CR) 137; cefazolin, cushing's (RPR) 974; cefazolin, beta-microglobulin, cystic fibrosis (PED) 1013; ganciclovir (ID) 7; lorazepam, metabolism (FF) 447; mirtazapine, metabolites (FF) 358; misoprostol, metabolites (FF) 278; nifedipine, metabolite (FF) 452; ofloxacin (FF) 841; propafenone, metabolites (FF) 198; propofol, metabolites (FF) 745; trimethoprim/sulfamethoxazole, metabolite (A) 647

Extravasation, doxorubicin, therapy (DIAS) 386, (L) 928

F-G

Family practice, see Ambulatory care

Famotidine, compared with cimetidine, acid suppression, critically ill patients 536 (Oct); interaction, diazepam, phenytoin, S19 (Oct), procainamide 520 (Oct), theophylline S18 (Oct), warfarin S20 (Oct); intravenous, continuous infusion, critically ill patients S42 (Oct); pharmacokinetics, S13 (Oct); stability, polyvinyl chloride syringes (SR) 588, refrigeration (RPR) 132; thrombocytopenia (L) 507

FDA, see Food and Drug Administration

FDA News (NC), see also, Food and Drug Administration; FDA Testing Genetics, 832; New Experiments in AIDS Therapies Under Study, 520; Pilot Drug Review Division, 520; Treatment IND, 104

Fellowships, see Education, pharmaceutical

Fellowships and Residencies, Arizona, University of Arizona, 938; California, University of California, San Francisco, 101, University of Southern California, 935; Connecticut, Hartford Hospital, 514, 935; Florida, Miami Veterans Administration Medical Center, 269, University of Florida, 938, 1043; Georgia, Mercer University, 185; Idaho, Boise Veterans Administration Medical Center, 185; Massachusetts, Brigham and Women's Hospital, 101; Missouri, University of Missouri-Columbia City, 101, 270, 1043; Western Missouri Health Center, 1043; Nebraska, A.M.I. St. Joseph Hospital, 935; New Jersey, Robert Wood Johnson University Hospital, 821, Rutgers University, 821; Ohio, Ohio State University, 938, 1043, University Hospitals of Cleveland, 935; Texas, University of Texas at Austin, 101, University of Texas at San Antonio, 102, 1043

Financial management, see Pharmacoeconomics

Fish oil, drug registration, Europe (L) 92

Flecainide, arrhythmias (NC) 736; cardiac arrest rate (O) 478; compared with propafenone (FF) 199

Floxacillin, incompatible, amoxicillin (L) 91, ciprofloxacin (L) 91, pefloxacin (L) 91

Flucytosine, interaction, amphotericin B (R) 672; malabsorption, Schwachman syndrome (SR) 782

Fludrocortisone acetate, orthostatic hypotension (G) 752

Fluorouracil, thrombotic microangiopathy (CR) 582

Fluoxetine, diabetic neuropathy (CR) 572; seizures (L) 428

Flurazepam, use, elderly (G) 610

Folic acid, hydroxycobalamin (L) 1033

Food, interaction, nifedipine sustained-release (RPR) 662

Food and Drug Administration, see also, FDA News (NC); Three Mile Island, potassium iodide status (O) 422

Formulary Forum, Clinical Pharmacology of Propofol: An Intravenous Anesthetic Agent, 743; Clozapine: A Novel Antipsychotic Agent, 109; Iofemine Hydrochloride 1 123; A New Radiopharmaceutical for Cerebral Perfusion Imaging, 19; Lorazepam: A Nonsteroidal Antihistamine with Once-Daily Dosing, 445; Misoprostol: A Prostaglandin E₂ Analog with Anticretory and Cytoprotective Properties, 276; Nimodipine in the Treatment of Subarachnoid Hemorrhage, 451; Ofloxacin: A Review, 839; Propafenone: A Novel Type II Antiarrhythmic Agent, 196; Recombinant Human Erythropoietin, 528; Role of Milrinone in the Management of Congestive Heart Failure, 357

Formulary system, cefotetan, compared with cefoxitin (PEC) 1024; cephalosporins S8 (JA)

Furosemide, interaction, aspirin (L) 340

Ganciclovir, adverse reactions (ID) 9; AIDS, review (ID) 5; clinical trial, cytomegalovirus (NC) 191; compared with acyclovir, cytomegalovirus (ID) 6; cytomegalovirus (O) 85, review (ID) 5; pharmacokinetics (ID) 7

Gastrointestinal disease, cytomegalovirus, ganciclovir (ID) 9

General News (NC), BIOSIS Connection Provides New Database on Multiple Sclerosis Research Projects, 736; Drug Death—A Danger of Hospitalization, 272; Drugs and Pharmaceuticals in the Biblical World, 192; Encainide/Flecainide Found Harmful in Cardiac Arrhythmia Study, 736; Grant for AIDS Research Laboratories, 272; IPSF 35th Congress in U.S., 736; 13 Confirmed as Board-Certified Nuclear Pharmacists, 949

Gentamicin, pharmacokinetics, mechanical ventilation (L) 923, service, cost-effectiveness (RPR) 33; with sulfites, sensitivity (L) 1032

Geriatrics, aspirin-related drug interactions (L) 340; assessment, functional (G) 847; auxiliary labels, ambulatory patients (G)

324; drug administration, functional abilities (G) 171; drug utilization, temazepam, diphenhydramine (L) 178; functional abilities, statistical tests (L) 513; NSAID, nephrotoxicity, lack (E) 74; nutritional supplements (G) 450; orthostatic hypotension (G) 750; psychotropic drug use (G) 610; textbook insufficiency (L) 1036; triazolam, long-term use (RPR) 290

Geriatrics and Gerontology, Assessment of Geriatric Patients' Functional Ability to Take Medication, 171; Changing Patterns of Psychotropic Drug Use in the Elderly: A Five-Year Update, 610; Effect of Auxiliary Prescription Labels on the Elderly Ambulatory Patient's Drug Knowledge, 324; Nutritional Supplements in the Ambulatory Elderly Population: Patterns of Use and Requirements, 490; Orthostatic Hypotension: Therapeutic Alternatives for Geriatric Patients, 750; The Relationship Between Comprehensive Functional Assessment and Optimal Pharmacotherapy in the Elderly Patient, 847

Globulin, immune, HIV-associated thrombocytopenia (TC) 158, Rho, HIV-associated thrombocytopenia (TC) 159

Glycopyrrolate, aspiration pneumonia (CC) 205

Gonadotropin-releasing hormone, infertility, men (DIAS) 246

Graves, Nina M., pharmacy's best teachers, American Association of Colleges of Pharmacy (NC) 832

H

Halazepam, use, elderly (G) 610

Hallucinations, midazolam (CR) 671

Haloperidol, compared with clozapine, schizophrenia (FF) 111; pregnancy (DIAS) 598

Halperin, Jerome A., Executive Director-Designate, United States Pharmacopoeial Convention (NC) 440

Hartshorn, Edward A., 1989 Distinguished Service Award, National Association of Boards of Pharmacy (NC) 632

Hartzeim, Abraham G., grant, John A. Hartford Foundation (NC) 272; Scientific Board, International Pharmaceutical Federation (NC) 104

Health care, home, congestive heart failure, amrinone infusion (SR) 59, osteomyelitis, infusion pump (CR) 379; India (IR) 252; self, traveler's diarrhea (PEP) 850

Health maintenance organizations, NSAID, therapeutic substitution (O) 76

Heart disease, ischemic, calcium antagonists, combination therapy (DIAS) 245

Heart failure, congestive, amrinone, home infusion (SR) 59

Hemodynamics, mechanical ventilation (CC) 316

Hemofiltration, continuous arteriovenous, trimethoprim/sulfamethoxazole (A) 649

Hemorrhage, subarachnoid, nimodipine (FF) 451, (L) 927

Hepatitis, disulfiram (CR) 872

Hepatotoxicity, phenytoin, review (A) 13

Herpes simplex virus, nonoxonyl 9 (DIAS) 602

HHS News (NC), Ganciclovir Trial for Cytomegalovirus, 191

Hill, Wendell T., Jr., Harvey A.K. Whitney Lecture Award, ASHP (NC) 440

Histamine-receptor antagonists, acid-suppressant properties, critically ill patients 536 (Oct); costs, heparin lock vs iv line S23 (Oct); drug utilization evaluation (L) 812; formulary considerations S29 (Oct); intravenous, continuous infusion, critically ill patients S40 (Oct); pharmacology S10 (Oct)

HIV, see Human immunodeficiency virus

Home health care, see Health care, home

Human immunodeficiency virus, *Pneumocystis carinii*, penicillamine (G) 806; thrombocytopenia, management (TC) 157; tumor infections (NC) 652; zidovudine, drug utilization (PEP) 698

Hydroxycobalamin, folliculitis (L) 1033

3-Hydroxyquinoline, formation rate, elimination rate constant (RPR) 375

Hypercarotenemia, oral contraceptives (L) 811

Hypercholesterolemia, probucol (DIAS) 880

Hyperglycemia, encainide (L) 711

Hypersensitivity, see Allergies

Hypertension acute, nifedipine (RPR) 855

Hypnotics, use, elderly (G) 611

Hypoalbuminemia, phenytoin, concentration (TM) 64, therapeutic monitoring (TM) 64

Hypocalcemia, carbamazepine (L) 1034

Hypoperfusion, cerebral, antihypertensives (A) 957

Hypotension, acute, etoposide (SR) 876; orthostatic, clonidine (G) 753, dihydroergotamine (G) 754, fludrocortisone acetate (G) 752, geriatrics (G) 750, indomethacin (G) 752, metoprolol (G) 753, midodrine (G) 754, monoamine oxidase inhibitors (G) 753, pindolol (G) 753, propranolol (G) 752, review (G) 750, vasopressor agents (G) 753, xamoterol (G) 754, yohimbine (G) 754

Hypotensive agents, cerebral hypoperfusion (A) 957; ischemia (SR) 238

Hysterectomy, cefonicid compared with cefoxitin, prophylaxis (RPR) 655

I-K

Ibuprofen, aseptic meningitis (L) 712; nephrotoxicity, lack, elderly (E) 74

Identification, foreign drugs (IR) 501

Ifosfamide, with mesna, treatment IND (NC) 104

Imipenem, compared with ofloxacin, bone infection (FF) 843

Imipramine, bulimia (DIAS) 882; compared with bromocriptine, depression (DIAS) 600; dosage, prediction (TM) 389; deep asleep (DIAS) 310

Immunoassay, homogeneous enzyme compared with HPLC, quinidine (TM) 999

Incompatibilities, amoxicillin/clavulanic acid, ciprofloxacin/amoxicillin, floxacillin, pefloxacin/amoxicillin (L) 91

Incontinence, drug-induced (G) 849

India, health care (IR) 252

Indomethacin, nephrotoxicity, lack, elderly (E) 74; orthostatic hypotension (G) 752

Industry, pharmaceutical, ethics, gifts (IR) 175

Infertility, men, gonadotropin-releasing hormone (DIAS) 246

Inflammatory bowel disease, ACTH (A) 968; aminosalicylic acid (A) 965; antidiarrheal agents (A) 969; betamethasone val-

1058 ■ DICP, The Annals of Pharmacotherapy ■ 1989 December, Volume 23

- compared with ciprofloxacin (L) 92; cephalosporins (S) 120 (JA), clindamycin, dosing (RPR) 980; liver transplant (L) 915, parenteral nutrition, 703; pharmacokinetic service (RPR) 33, physician prescribing, clinical pharmacy impact (PEC) 417, prescribing, outpatients (PEC) 497; evaluation, medicine (L) 431; histamine, receptor antagonists, heparin lock vs iv (atc) 523 (Oct); research, clinical trials (PEC) 694, definition (PEC) 693, design (PEC) 695
- Pharmacoeconomics (PEC), Cost Effectiveness of Two Interventions for Reducing Outpatient Prescribing Costs, 497; Effect of Clinical Pharmacy Services on the Quality of Family Practice Physician Prescribing and Medication Costs, 417; Formulary Conversion of Cefotaxim Usage to Cefotetan: Experience at a Large Teaching Hospital, 1024; Pharmacoeconomic Research and Clinical Trials: Concepts and Issues, 693**
- Pharmacoeconomics (PEC), A Clinical Pharmacy-Oriented Drug Surveillance Network: Results of a Nationwide Antibiotic Utilization Review of Bacterial Pneumonia—1987, 162; Pharmacists' Self-Medication for Traveler's Diarrhea, 800; Prescription Drug Use Patterns of Human Immunodeficiency Virus-Infected Patients Taking Zidovudine, 698**
- Pharmacokinetics, N⁶-acetylsulfamethoxazole, renal dysfunction (A) 649; aminocaproic acid, hemodialysis (L) 522; antibiotics, microbiological activity, children (S) 16 (JA); cimetidine (S) 103; clinical service, aminoglycosides (L) 622, cost-effectiveness (RPR) 33; clozapine (FF) 110; digoxin, concentrations (L) 717, malabsorption syndrome (RPR) 764, toxicity (L) 93; dosing rate change (TM) 468; drug interactions, organic anions, cations (A) 119; erythropoietin (FF) 528; famotidine (S) 13 (Oct); ganciclovir (DD) 7; gentamicin, mechanical ventilation (L) 923; 3-hydroxyquinoline (RPR) 375; interaction (FF) 20; lorazepam (FF) 446; mechanical ventilation (CC) 316; milrinone (FF) 358; misoprostol (FF) 278; nimodipine (FF) 454; nizatidine (S) 103; ofloxacin (FF) 840; phenytoin, effect of cimetidine, famotidine, ranitidine (S) 19 (Oct), equation accuracy (L) 621, renal failure, hypocalcemia (TM) 64; piaziquantel (RPR) 29; procainamide, effect of cimetidine, famotidine, ranitidine (S) 103; propafenone (FF) 197; propofol (FF) 745; ranitidine (S) 103; theophylline, effect of famotidine, cimetidine, ranitidine (S) 103; tobramycin, probability assessment (TM) 240; trimethoprim/sulfamethoxazole (A) 646; vancomycin, Bayesian method (RPR) 294; warfarin, effect of cimetidine, famotidine, ranitidine (S) 103 (Oct)**
- Pharmacology, cephalosporins (S) 120 (JA); cocaine (A) 639; gastrointestinal drugs (S) 103 (Oct); hiofetine (FF) 19; lorazepam (FF) 445; milrinone (FF) 357; propafenone (FF) 197**
- Pharmacotherapy, see also, Pharmacy, clinical; BPS approval (E) 909; BPS Specialty Council meeting (NC) 736; certification (E) 909 (E) 1031; definition (E) 73; DICP title (E) 73**
- Pharmacotherapy Case Reports, A Variant of the Chemotherapy-Associated Erythrodysplasia Syndrome Related to High-Dose Cyclophosphamide, 776; Allergic Reaction to Antipyrine, a Marker of Hepatic Enzyme Activity, 38; Amoxicillin-Induced Neuroleptic Malignant Syndrome, 50; Anaphylactic Reaction to Streptokinase with First Exposure: Case Report and Review of the Literature, 869; Carbamazepine Clearance in Hemodialysis and Hemoperfusion, 137; Delusions of Parasitosis: A Case Report and Management Guidelines, 304; Disulfiram-Induced Hepatitis: Case Report and Review of the Literature, 872; Drug-Induced Esophageal Injury: A Case Report of Percutaneous, 227; Erythromycin-Induced Cystitis, 668; Heinz-Body Hemolytic Anemia Associated with Phenazopyridine and Sulfonamide, 140; Idiopathic Thrombocytopenia Associated with Triphasic Oral Contraceptives, 773; Intravenous Erythromycin Lactobionate-Induced Severe Nausea and Vomiting, 49; Isoflurane for the Management of Status Epilepticus, 579; Leukopenia with Neutropenia Associated with Teicoplanin Therapy, 45; Myocardial Infarction After Dipyrindamole-Assisted Thallium-201 Imaging, 665; Prolonged Use of Intravenous Isoflurane and Rifampin, 48; Ranitidine-Induced Chest Pain, 224; Relief of Diabetic Neuropathy with Fluoxetine, 227; Erythromycin-Associated Thrombocytopenia Secondary to Poor Compliance, 382; Streptokinase-Induced Anaphylaxis, 984; Theophylline-Isoflurane Interaction, 143; Thrombotic Microangiopathy Associated with Chemotherapy: Case Report and Review of the Literature, 382; Use of an Ambulatory Infusion Pump in a 12-Year-Old with *Salmonella* Osteomyelitis, 379**
- Pharmacy, clinical, see also, Pharmacotherapy; academic appointment (O) 920; antibiotic utilization, nationwide review (PEP) 162, drug cost (PEC) 417, drug information needs (L) 266, education (ET) 912, Institutional Review Board participation (L) 431, (L) 816, pharmacokinetics service, aminoglycosides (RPR) 33, (L) 622, physician prescribing (PEC) 417, (PEC) 497, (RPR) 770, costs (PEC) 417, textbooks (L) 430; community, consumer advice (RPR) 218, verbal communication (RPR) 862; hospital, drug bulletins, effectiveness (RPR) 330; education, distance (L) 926, Japan (RPR) 334; nuclear, board certification, (atc) 949; publishing (E) 809**
- Pharmacy Council, Cholesterol, see Association News (NC)**
- Phenazopyridine, organic nitrate-induced methemoglobinemia (A) 284; with trimethoprim/sulfamethoxazole, hemolytic anemia (CR) 140**
- Phenelzine, bulimia (DIAS) 883**
- Phenobarbital solution, parenteral solution, rectally administered (RPR) 365**
- Phenothiazines, pregnancy (DIAS) 598; sudden infant death syndrome (DIAS) 795**
- Phenytoin, concentration, renal failure, hypocalcemia (TM) 64; cross-sensitivity, carbamazepine (SK) 235; quation accuracy (L) 621; hepatotoxicity, renal (A) 13; interaction, cimetidine, famotidine, ranitidine (S) 19 (Oct), enteral feeding (DIAS) 796**
- Phi Delta Chi Fraternity, see Association News**
- Physicians, ethics, pharmaceutical industry, gifts (R) 175; prescribing, clinical pharmacy impact (PEC) 417, estrogen replacement therapy, 977; pharmacist intervention (RPR) 770; prescribing costs, clinical pharmacist intervention (PEC) 497**
- Pimozide, parasitosis delusions (CR) 304**
- Pindolol, orthostatic hypotension (G) 733**
- Pneumococcal polysaccharide vaccine, guidelines (NC) 351**
- Pneumocystis carinii, pneumonia, pentamidine, aerosol (L) 718, (O) 806; trimethoprim/sulfamethoxazole (DIAS) 687**
- Pneumonia, bacterial, antibiotic utilization, nationwide review (PEP) 162; *Pneumocystis carinii*, pentamidine, aerosol (L)**
- 718, (O) 806; trimethoprim/sulfamethoxazole (DIAS) 687**
- Pneumonia, aspiration, ataxia (CC) 205; cimetidine (CC) 205; glycopyrrolate (CC) 205; metoprolol (CC) 206; pathophysiology (CC) 203; ranitidine (CC) 205**
- Poliomyelitis, incidence, America (NC) 832**
- Polyethylene glycol, with iso-osmolar electrolyte solution, intestinal lavage, children (DIAS) 1008**
- Potassium iodide, Three Mile Island (O) 422**
- Praziquantel, comparative availability (RPR) 29**
- Prazosin, benign prostatic hypertrophy (DIAS) 474; cerebral hyperperfusion (A) 959**
- Prednisolone, no interaction, ketoconazole (RPR) 858**
- Prednisone, inflammatory bowel disease (A) 967; interaction, aspirin (L) 340**
- Pregnancy, antipsychotics (DIAS) 598**
- Prescribing, clinical pharmacy impact (PEC) 417, (PEC) 497; costs, pharmacist education (RPR) 770; estrogen replacement therapy (RPR) 977; psychotropics, mental retardation (L) 24**
- Procainamide, interaction, cimetidine, ranitidine (A) 120, trimethoprim (A) 121; pharmacokinetics, effect of cimetidine, famotidine, ranitidine (S) 103 (Oct)**
- Prochlorperazine, sudden infant death syndrome (DIAS) 796**
- Propafenone, sudden infant death syndrome (DIAS) 795; toxicity (L) 89**
- Propafenone, adverse reactions (FF) 200; compared with amiodarone, disopyramide, flecainide, mexiletine, quinidine (FF) 199; interaction, digoxin, warfarin (FF) 198; interaction, lack, cimetidine (FF) 198; pharmacokinetics (FF) 197; pharmacology (FF) 196, review (FF) 196**
- Propylthiouracil, cefonicol compared with cefoxitin, hysterectomy (RPR) 655**
- Propofol, adverse reactions (FF) 747; compared with isoflurane, midazolam (FF) 747; pharmacodynamics (FF) 743; pharmacokinetics (FF) 745; review (FF) 743**
- Propranolol, cerebral hyperperfusion (A) 959; compared with atenolol, nifedipine (DIAS) 248; compared with metoprolol, nadolol, timolol, nifedipine (DIAS) 248; interaction, aspirin (L) 340; orthostatic hypotension (G) 732**
- Prostaglandin E₂, see Dinoprost**
- Prostaglandin F₂-alpha, see Dinoprost**
- Prostatic hypertrophy, benign, prazosin (DIAS) 474**
- Psychotropics, see Psychotherapeutic agents**
- Psychotherapeutic agents, prescribing, mental retardation (L) 24**
- Propritiol, sleep apnea (DIAS) 308**
- Publishing, internship (L) 178; pharmacist (E) 809**
- Pyrazinamide, interaction, theophylline (L) 258**
- Pyrimethamine, with sulfadoxine, toxic epidermal necrolysis (NC) 192**

Q-R

- Quinidine, compared with propafenone (FF) 199; EMIT compared with HPLC (TM) 999**
- Quinolones, bacterial resistance (A) 556; incompatibilities, penicillins (L) 91**
- Ranitidine, aspiration pneumonia (CC) 205; chest pain (CR) 224; compared with cimetidine, drug utilization evaluation (L) 812; compared with misoprostol (FF) 279; interaction, phenytoin (S) 103, procainamide (S) 103, theophylline (S) 103, warfarin (S) 103; interaction, possible, warfarin (TC) 675; procainamide (A) 120; intravenous, continuous infusion, critically ill patients (S) 103 (Oct); pharmacokinetics (S) 103 (Oct); thrombocytopenia (L) 508**
- Registration, fish oil, Europe (L) 92**
- Renal dysfunction, NSAID (E) 94; *Pneumocystis carinii* pneumonia, trimethoprim/sulfamethoxazole (DIAS) 687; trimethoprim/sulfamethoxazole, renal (A) 13**
- Renal failure, phenytoin, concentration, therapeutic monitoring (TM) 64**
- Renal transport, mechanisms, review (A) 116**
- Research/Practice Reports, A Comparison of Sublingual Nifedipine Versus Nitroglycerin in the Treatment of Acute Angina Pectoris, 562; A Trial Using Early Preoperative Administration of Cefonicol for Antimicrobial Prophylaxis with Hysterectomies, 655; Absorption of Digoxin from Tablets and Capsules in Subjects with Malabsorption Syndromes, 764; Albumin Utilization in a University Hospital, 214; An Objective Method of Compliance Assessment with Metered-Dose Inhalers, 128; Communication of Verbal Information by Community Pharmacists, 862; Comparative Bioavailability of Piaziquantel Tablets, 29; Consumer Use of Nondispensing Professional Pharmacy Services, 218; Cost Analysis of Two Clindamycin Dosing Regimens, 980; Disposition of 3-Hydroxyquinidine in Patients Receiving Initial Intravenous Quinidine Gluconate for Electrophysiology Testing of Ventricular Tachycardia, 375; Effect of Assay Methodology on the Prediction of Lithium Maintenance Dosage, 372; Effect of Food on Nifedipine Sustained-Release Preparation, 662; Effects of Magnesium Citrate and Cidindium Bromide on the Excretion of Activated Charcoal in Normal Subjects, 26; Estimation of Creatinine Clearance in Patients with Cushing's Syndrome, 974; Estrogen Replacement Therapy: A Pilot Survey of Primary Care Physicians in West Virginia, 977; Evaluation of Long-Term Triazolam Use in an Ambulatory Veterans Administration Medical Center Population, 290; Evaluation of Three Methods for Determining Initial Vancomycin Doses, 123; Evaluation of a Bayesian Method for Predicting Vancomycin Dosing, 294; Impact of Education by Clinical Pharmacists on Physician Ambulatory-Care Prescribing of Generic Versus Brand-Name Drugs, 770; Impact of a Clinical Pharmacokinetic Service on Patients Treated With Aminoglycosides for Gram-Negative Infections, 33; Mepredine Binding to Isolated Alpha₁-Acid Glycoprotein and Albumin, 568; Nifedipine in the Treatment of Hypertensive Episodes in the Coronary Care Unit, 855; Relative Bioavailability of Rectally Administered Phenobarbital Sodium Parenteral Solution, 565; Serum Inhibitory and Bactericidal Activity of Ciprofloxacin Following Intravenous Administration, 456; Stability of Famotidine in Minibags Refrigerated and/or Frozen, 132; Steroid-Specific Effects of Ketoconazole on Corticosteroid Disposition: Unaltered Prednisolone Elimination, 858; Survival of Beta-Lactamase-Producing and -Nonproducing Bacteria in Intravenous Solutions, 210; Therapeutic Monitoring of Cyclosporine Following Pediatric Bone Marrow Transplantation: Problems with Sampling from Silicone Central Venous Lines, 300; Thiopental-Sparing Properties of Butorphanol/Diazepam for Induction of Anesthesia in Ambulatory Gynecologic Surgery, 659; Tobramycin Administration and Blood Sampling Through a Dual-Lumen Peripheral Intravenous Catheter, 460**
- Residencies, see Education, pharmaceutical; Fellowships and Residencies**
- Resistance, bacterial, antibiotics (A) 556**
- Retinitis, cytomegalovirus, ganciclovir (ID) 8**
- Rho Chi Lecture, Positioning Pharmacy for the 21st Century, 706**
- Ribavirin, contact lens damage (L) 428**
- Rifampin, bacterial resistance (A) 557; thrombocytopenia (CR) 382; with isoniazid, intravenous (CR) 48**
- Röntgenographic agents, adverse reactions, review (L) 925**
- Rotschaf, John C., pharmacy's best teachers, American Association of Colleges of Pharmacy (NC) 832**
- Rubella, incidence (NC) 520**
- Rybak, Michael J., Merck Foundation Fellowship Award in Infectious Disease (NC) 832**

S

- SC48334, clinical testing approved (NC) 520**
- Schantz, Jerome J., 1989 ASHP Research and Education Foundation Award, Achievement for Sustained Contributions to the Literature of Hospital Pharmacy (NC) 736**
- Shwachman syndrome, flucytosine, malabsorption (SR) 782**
- Shwachman, carbamazepine, hypocalcemia (L) 1034**
- Seizures, see also Status epilepticus; aminocaproic acid (SR) 780; fluoxetine (L) 428; incidence, bupropion (O) 704**
- Seligline, treatment IND (NC) 104**
- Short Reports, Acute Hypotensive Reaction to Etomidate with Successful Rechallenge: Case Report and Review of the Literature, 876; Bioequivalence of Two Leucovorin Calcium Tablet Formulations, 153; Bullous Pemphigoid Associated with Captopril, 63; Carbamazepine Toxicity Precipitated by Intravenous Erythromycin, 878; Cardiac Dysrhythmia with the Use of Clonidine in Explosive Disorder, 465; Convulsions Induced by Aminocaproic Acid Infusion, 780; Cross-Sectional Study of the Ethics of Pharmacy Students, 590; Diabetogenic Effect of Nifedipine, 236; Disopyramide and N-Monodansyl Disopyramide in Serum and Breast Milk, 56; Evaluation of Cefonicol Use in a General Hospital, 154; Granulocytopenia and Thrombocytopenia Associated with Combination Therapy of Amphotericin B and Low-Dose Flucytosine in a Patient with Cryptococcal Meningitis, 672; Hemodynamic Vertebral Basilar Insufficiency as an Adverse Effect of Antihypertensive Therapy, 238; Home Intermittent Amrinone Infusions in Terminal Congestive Heart Failure, 59; Hostility and Hallucinations as a Consequence of Midazolam Administration, 671; Malabsorption of Flucytosine in a Pediatric Patient with Shwachman Syndrome, 782; Methazolamide-Associated Temporary Leukopenia and Thrombocytopenia, 58; Panic Attacks and Major Depression After Discontinuation of Long-Term Diazepam Abuse, 989; Phenytoin-Carbamazepine Cross-Sensitivity, 235; Precipitation of Benzodiazepine Withdrawal Following Sudden Discontinuation of Midazolam, 151; Quotation Accuracy in Review Articles, 594; Stability of Caffeine Injection in Intravenous Admixtures and Parenteral Nutrition Solutions, 466; Stability of Intravenous Famotidine Stored in Polyvinyl Chloride Syringes, 588; Verapamil-Associated Stevens-Johnson Syndrome, 987**
- Simonson, William, George F. Archambault Award, American Society of Consultant Pharmacists (NC) 1054**
- SI units, see International System of Units**
- Sodium bicarbonate, extravasation, doxorubicin (DIAS) 386**
- Sodium nitrate, organic nitrate-induced methemoglobinemia (A) 284**
- Sodium nitropruside, organic nitrate-induced methemoglobinemia (A) 284**
- Software Received, 433**
- Software Reviews, Family Care Software (J.W. Eastman and R.S. Kurnetz), 217; Patient Education Pediatric Software Version 2.2 (B. Schmitt), 181**
- Sotalol, compared with labetalol, metoprolol, oxprenolol, cerebral hyperperfusion (A) 959**
- Spirituality, pharmaceutical education (O) 337**
- Splenectomy, HIV-associated thrombocytopenia (TC) 158**
- Stability, caffeine, iv admixtures, parenteral nutrition (SR) 466, (L) 928, syringes (L) 1035; cefazolin, iv solutions (L) 615; cimetidine hydrochloride, copper sulfate, TPN (L) 429; famotidine, polyvinyl chloride syringes (SR) 588, refrigerated/frozen (S) 444 (Oct), (RPR) 132**
- Staphylococcus aureus, survival, iv solution (RPR) 210**
- Statistics, chi-square (L) 513; linear regression, method comparison (CS) 891**
- Status asthmaticus, see also, Asthma; theophylline (TC) 995**
- Status epilepticus, see also, Seizures; isoflurane (CR) 579**
- Steroids, cortico-, cardiovascular adverse reactions, review (DIR) 1019; extravasation, doxorubicin (DIAS) 386; HIV-associated thrombocytopenia (TC) 157; inflammatory bowel disease (A) 967**
- Streptokinase, anaphylaxis (CR) 869, (CR) 984**
- Stress, amino acids, branched chain (A) 399, (TC) 411**
- Stevens-Johnson syndrome, verapamil (SR) 987**
- Stroke, isoflurane hydrochloride (FF) 20**
- Sudden infant death syndrome, prochlorperazine (DIAS) 796; propafenone (DIAS) 795; trimiprazine (DIAS) 795**
- Sulfadoxine, with pyrimethamine, toxic epidermal necrolysis (NC) 192**
- Sulfamethoxazole, with trimethoprim, adverse reactions (A) 650, compared with ofloxacin, urinary tract infection (FF) 842, dialysis, hemofiltration (A) 649, dosage (A) 652, interaction, warfarin (L) 619, pharmacokinetics (A) 646, phenazopyridine, hemolytic anemia (CR) 140, *Pneumocystis carinii* pneumonia, renal impairment (DIAS) 687, renal dysfunction (A) 646**
- Sulfasalazine, inflammatory bowel disease (A) 965**
- Sulfites, sensitivity, with gentamicin (L) 1032**

Sulfonamides, bacterial resistance (A) 557
Surgery, amiodarone, intraoperative adverse effects (CC) 757
Inflammatory bowel disease (A) 970
Sympatholytic agents, migraine headache, prophylaxis (DIAS) 248
Symposia, Choosing Cephalosporins for the Formulary: Developmental Pharmacology: Relationship to Drug Use, S21 (JA); Comparison of the Parenteral Histamine₂-Receptor Antagonists, S17 (Oct); Cost Considerations of Intravenously Administered Histamine₂-Receptor Antagonists, S23 (Oct); Interaction of Microbiology and Pharmacokinetics in the Selection of Appropriate Antibiotic Therapy, S16 (JA); Introduction: Aims of the Symposium, S9 (Oct); Introduction, S7 (JA); Monitoring Antibiotic Use in the Hospital, S13 (JA); Pharmacoeconomic Aspects and Formulary Considerations Related to Histamine₂-Receptor Antagonists, S29 (Oct); Protein Binding: What Does it Mean?, S27 (JA); Safety and Acid-Suppressant Properties of Histamine₂-Receptor Antagonists for the Prevention of Stress-Related Mucosal Damage in Critical Care Patients, S36 (Oct); Stability of Famotidine in Minibags Refrigerated and/or Frozen in Total Parenteral Nutrition Solutions, S44 (Oct); The Pharmacology of Antileukotriene Drugs, S10 (Oct); Use of Continuous Infusion of Histamine₂-Receptor Antagonists in Critically Ill Patients, S40 (Oct)

T

Teicoplanin, leukopenia, neutropenia (CR) 45
Temazepam, use, elderly (G) 610; utilization, nursing homes (L) 178
Teniposide, treatment IND (NC) 104
Teratogenicity, cocaine (A) 639
Terbutaline, inhaler, compliance (RPR) 128
Terfenadine, compared with loratadine (FF) 447
Tetracycline, bacterial resistance (A) 557
Theophylline, dosing, guidelines (L) 113; interaction, cimetidine, famotidine, ranitidine S18 (Oct); interaction, lack, ofloxacin (FF) 843; ionized (CR) 143, pyranol pamoate (L) 258; status asthmaticus (TC) 995; toxicity, cefaclor administration (L) 339; uric acid concentrations, children (L) 714
Therapeutic Controversies, Alternative Dosing Strategy for Aminoglycosides: Impact on Efficacy, Nephrotoxicity, and Ototoxicity, 788; Do All Histamine₂-Antagonists Cause a Warfarin Drug Interaction?, 675; Do Parenteral Nutrition Solutions with High Concentrations of Branched-Chain Amino Acids Offer Significant Benefits to Stressed Patients?, 411; Human Immunodeficiency Virus-Associated Thrombocytopenia, 157; Should We Stop Using Theophylline for the Treatment of the Hospitalized Patient with Status Asthmaticus?, 995
Therapeutic Monitoring, Accuracy of Two Equations in Determining Normalized Phenytoin Concentrations, 64; Comparison of Assay Procedures Used to Measure Total and Unbound Concentrations of Quinidine, 999; Predictive Techniques Applied to Imipramine Therapeutic Drug Monitoring, 389; Probability Assessment Approach to Therapeutic Drug Monitoring: Tobramycin, 240; Time to Steady State Following a Change in Dosing Rate, 468
Therapeutic monitoring, antibiotics, microbiology, pharmacokinetics S16 (JA); assay procedures, comparison (TM) 999; carbamazepine, hemodialysis (CR) 137; digoxin, pharmacokinetics (L) 717, toxicity (L) 93; disopyramide, breast milk (SR) 56, serum (SR) 56; imipramine, prediction (TM) 389; lithium, flame compared with absorption spectrophotometric assay (RPR) 372; N-monodesalkyl disopyramide, breast milk, serum (SR) 56; phenytoin, hypocalcemia, renal failure (TM) 64; trimethoprim/sulfamethoxazole (A) 652; urinary, probability assessment (TM) 240; vancomycin, Bayesian dosing (RPR) 294

Therapeutic substitution, see Equivalency, therapeutic
Thiamine, deficiency, total parenteral nutrition (NC) 271
Thiopental, compared with butorphanol/diazepam, anesthesia induction (RPR) 659
Thioridazine, neuroleptic malignant syndrome (L) 712
Three Mile Island, potassium iodide, manufacture, stockpiling (O) 422
Thrombocytopenia, cimetidine (L) 177; famotidine (L) 507; HIV-associated, management (TC) 157; methazolamide (SR) 58; ranitidine (L) 508; rifampin (CR) 382
Thromboembolism, idiopathic, triphasic oral contraceptives (CR) 773
Thrombotic microangiopathy, antineoplastic agents (CR) 582
Timolol, compared with propranolol, migraine (DIAS) 248
Tixocortol pivalate, inflammatory bowel disease (A) 968
Tobramycin, dual-lumen IV catheter (RPR) 460; pharmacokinetic service, cost-effectiveness (RPR) 33; probability assessment, therapeutic monitoring (TM) 240
Tocaine, ar-lactic anemia (L) 90; myotonic dystrophy (DIAS) 69
Tolazamide, interaction, aspirin (L) 340
Toxicity, acetaminophen, delayed acetylcysteine absorption (L) 509; chlorpromazine (L) 510; digoxin, concentrations (L) 93; digoxin-like immunoreactive substance (L) 93; ethylene glycol, osmolality formula (L) 432; promethazine (L) 89; theophylline, cefaclor administration (L) 339
Transplantation, bone marrow, cyclosporine, silicone central venous line: sampling (RPR) 300; liver, cost (L) 925
Trazodone, sleep apnea (DIAS) 311
Triazolam, long-term use (L) 814; use, elderly (RPR) 290, (G) 610
Trifluoperazine, compared with clozapine, schizophrenia (FF) 111
Trimethoprim, sudden infant death syndrome (DIAS) 795
Trimethoprim, bacterial resistance (A) 556; interaction, procainamide (A) 121; with sulfamethoxazole, adverse reactions (A) 650, compared with ofloxacin, urinary tract infection (FF) 842; dialysis, hemofiltration (A) 649; dosage (A) 652, interaction, warfarin (L) 619; pharmacokinetics (A) 646, phenazopyridine, hemolytic anemia (CR) 140, *Pneumocystis carinii* pneumonia, renal impairment (DIAS) 687, renal dysfunction (A) 646
Trimethoprim, treatment IND (NC) 104
Tryptophan, sleep apnea (DIAS) 311
Tuberculosis, isoniazid with rifampin (CR) 48
Tubocurarine chloride, dosage, burns (DIAS) 1007

U-Z

Ulcers, misoprostol, review (FF) 278
Uric acid, concentrations, theophylline, children (L) 714
USPHS—CDC News (NC), Cholera Vaccine, 191; Colorectal Cancer Incidence and Mortality, 1053; Deaths Associated with Thiamine-Deficient Total Parenteral Nutrition, 271; Deaths from Diabetes: United States, 1986, 949; Eradicating Polio myelitis from the Americas, 832; Estimate of Total Number of HIV Infections, 632; Incidence of Measles, 832; Measles Prevention, 191; Pneumococcal Polysaccharide Vaccine, 351; Pyrimethamine/Sulfadoxine-Associated Fatal Reaction in an HIV-Infected Man, 192; Rubella and Congenital Rubella Syndrome: United States, 1985-88, 520; Trends in Lung Cancer Incidence, 1973-86, 1053
Vancomycin, dosing, Bayesian method (RPR) 294; dosing methods compared (RPR) 123, (L) 618; with celecoxib, pseudomonas colitis (DIAS) 70
Vasopressor agents, orthostatic hypotension (G) 753
VaxSyn HIV-1, clinical testing approved (NC) 520
Ventilation, mechanical, gentamicin, pharmacokinetics (L) 923; pharmacokinetic implications (C) 316
Ventricular tachycardia, 3-hydroxyquinidine, pharmacokinetics (RPR) 375
Verapamil, acute myocardial infarction, review (DSP) 540; cerebral hypoperfusion (A) 960; continuous infusion (DIAS) 1005; Stevens-Johnson syndrome (SR) 987; with nifedipine, ischemic heart disease (DIAS) 245
Vinblastine, thrombotic microangiopathy (CR) 583
Vinca alkaloids, thrombotic microangiopathy (CR) 583
Vindesine, thrombotic microangiopathy (CR) 583
VIP News (NC), Campbell, R. Keith, 832; Cardoni, Alex A., 192; Doluisio, James T., 352; Edwards, David J., 832; Graves, Nina M., 832; Halperin, Jerome A., 440; Hartshorn, Edward A., 632; Hartzema, Abraham G., 104, 272; Hill, Wendell T., Jr., 440; Nahata, Milap C., 440, 949; Ratschauer, John C., 832; Rybak, Michael J., 832; Schentag, Jerome J., 736; Simonson, William, 1054; Viass, Peter H., 440; Weaver, Lawrence C., 272; White, Eugene V., 520
Vitamin B₁₂, see Hydroxocobalamin
Vitamins, geriatrics (G) 490
Viass, Peter H., Associate Director, Technology Advancement Center, Director of Drug Technology Research, University Hospital Consortium, Inc. (NC) 440
Vomiting, nausea, erythromycin lactobionate (CR) 40
Warfarin, interaction, propafenone (FF) 198; interaction, possible, cimetidine (TC) 673, ranitidine (TC) 675; pharmacokinetics, effect of cimetidine, famotidine, ranitidine S20 (Oct) 509; Weaver, Lawrence C., Remington Medal, American Pharmaceutical Association (NC) 272
White, Eugene V., Outstanding Pharmacy Alumnus Award, Medical College of Virginia Alumni Association (NC) 520
Withdrawal, alprazolam, neonates, breast feeding (L) 614; midazolam (SR) 151; nicotine, clonidine (DIAS) 473, (L) 1035
Xamoterol, orthostatic hypotension (G) 754
Xylitol, dental caries (DIAS) 691
Yohimbine, orthostatic hypotension (G) 754
Zidovudine, drug utilization (PEP) 698

AUTHOR INDEX

A

Abate, Marie A. (author) book review, 262; (coauthor) see Hammond, Douglas, 339
Ackerman, Bruce H. (author) Author's Reply: Vancomycin Dosing Methods (L) 618; (author) book review, 95; (author) Disposition of 3-Hydroxyquinidine in Patients Receiving Initial Intravenous Quinidine Gluconate for Electrophysiology Testing of Ventricular Tachycardia (RPR) 375; (author) Evaluation of Three Methods for Determining Initial Vancomycin Doses (RPR) 123
Ackerman, Deborah J. (coauthor) see Ackerman, Bruce H., 375
Adachi, Katsuro (coauthor) see Hirota, Noritake, 714
Afsar, Mary (coauthor) see Larjani, Ghassam E., 743
Akpan, Udo E. (coauthor) see Hugo, Peter G., 210
Aldinger, Janice (coauthor) see Babul, Najib, 713
Alexander, Bruce (author) book review, 817
Alexander, Michael R. (author) Albumin Utilization in a University Hospital (RPR) 214; (editor) Therapeutic Controversies, 157, 411
Ameer, Barbara (coauthor) see Burnette, Pearl K., 382
Anderson, Philip O. (author) Neonatal Alprazolam Withdrawal—Possible Effects of Breast Feeding (L) 614
Andre, Archambault (coauthor) see Laurier, Claudine, 862
Andre-Pierre, Constantopoulos (coauthor) see Laurier, Claudine, 862
Andrew, Angela (coauthor) see Gallastegui, Carmen, 1033
Anisete, Luisita V. (coauthor) see Moysa, Gerald D., 712
Antalek, Matthew (coauthor) see Tisdale, James E., 984
Anunciabay, P. Galdos (coauthor) see Pan, C. Vidal, 89
Appelman, Maria D. (coauthor) see Chin, Alfred, 980
Archambault, Andre (coauthor) see Laurier, Claudine, 862
Arnau, Josep M. (coauthor) see Rodriguez, Carlos, 154
Aschoff, Carl R. (coauthor) see Christilles, Elizabeth A., 617

B

Babich, Michele (author) Calcium-Channel Blockers in Acute Myocardial Infarction (DSP) 538
Babonis, Elena (author) Clozapine: A Novel Antipsychotic Agent (FF) 109

Babul, Najib (author) Impact of Theophylline Dosing Guidelines (L) 713
Bachmann, Kenneth A. (coauthor) see Mauro, Laurie Slack, 64, 621
Bader, Augustinus (author) Reversible Hematologic Suppression During Ranitidine Treatment (L) 508
Bailey, Robert T., Jr. (coauthor) see Jones, James B., 88, 276; (coauthor) see Nwakama, Patrick E., 227
Baker, Brian A. (coauthor) see Lin, Anne Y.F., 987
Baker, Daniel E. (coauthor) see Jinks, Martin J., 800
Balfour, Henry H., Jr. (coauthor) see Fletcher, Courtney V., 5
Bansal, Pratibha (coauthor) see Yudenfreund, Shari M., 614
Baptista, Richard J. (author) Home Intermittent Amrinone Infusions in Terminal Congestive Heart Failure (SR) 59; (coauthor) see Milrano, Francis P., 429
Barenholtz, Hedva A. (author) book review, 96; (author) Internship in Pharmaceutical Publishing (L) 178; (author) Loratadine: A Nonsedating Antihistamine with Once-Daily Dosing (FF) 445
Bartle, William R. (author) Delayed Acetaminophen Toxicity Despite Acetylcysteine Use (L) 509
Bauman, Jerry L. (coauthor) see Parker, Robert B., 196
Bednarczyk, Edward M. (author) Anaphylactic Reaction to Streptokinase with First Exposure: Case Report and Review of the Literature (CR) 869
Bell, Judy L. (coauthor) see Ellsworth, Allan J., 56
Bellenger-McCleery, Renee A. (coauthor) see Seifert, Charles P., 40
Ben-Nissan, David S. (coauthor) see Cohen, Amos M., 58
Benito, Salvador (coauthor) see Triguera, Carlos, 923
Bennett, William M. (author) Comment: Chlorpromazine Sudden Death (L) 510
Berbat, Con G. (coauthor) see Plumridge, Richard J., 330
Berg, Jeffrey A. (author) Comment: Levobupropione Bioequivalence (L) 812
Berman, David E. (coauthor) see Burnakis, Thomas G., 671
Berne, Thomas V. (coauthor) see Chin, Alfred, 980
Berry, Phillip L. (coauthor) see Kearns, Gregory L., 1013
Bess, David T. (coauthor) see Steele, Malcolm A., 497
Biedle, Paul (author) Myocardial Infarction After Dipyrindole-Assisted Thallium-201 Imaging (CR) 665
Biscarini, Luciano (coauthor) see Del Favero, Albano, 45
Biswas, Brack A. (coauthor) see Rapp, Robert P., 899
Bjornsson, Darrel C. (author) Prescription Drug Use Patterns of Human Immunodeficiency Virus-Infected Patients Taking Zidovudine (PEP) 698
Blaiz, Diane (author) Comment: Foreign Drug Identification (L) 1036
Bleidi, Barry A. (coauthor) see Moss, Jeffrey T., 260
Blouin, Robert A. (coauthor) see Hattin, Jimmi, 974
Blum, Robert A. (author) Aging and Nonsteroidal Antiinflammatory Drug-Induced Renal Dysfunction (E) 74
Bocchini, Joseph A., Jr. (coauthor) see Kearns, Gregory L., 1013
Boekenogen, Steven J. (coauthor) see Grasel, Thaddeus H., Jr., 162
Bonal, Joaquin (coauthor) see Gallastegui, Carmen, 1033
Bone, William S. (author) Delusions of Parasitosis: A Case Report and Management Guidelines (CR) 304; (author) Psychotropic Drug Use in Institutionalized People with Mental Retardation (L) 924
Bootman, J. Lyle (author) Pharmacoeconomic Research and Clinical Trials: Concepts and Issues (PEC) 693; (coeditor) see McGhan, William P., 417, 497, 693, 1024
Bosse, John A. (author) Bacterial Resistance to Antibiotics: Mechanisms and Prevalence in Hospitals and Nursing Homes (A) 556
Boyce, Eric G. (author) Cross-Sectional Study of the Ethics of Pharmacy Students (SR) 590
Brass, Corstiaan (coauthor) see Ludwig, Elizabeth A., 858
Breitenbach, Robert (coauthor) see Gray, David R.P., 92
Briceland, Laurie L. (coauthor) see Smith, Karen S., 1024
Briggs, Gerald G. (author) book review, 1038
Brown, Candace S. (coauthor) see Marken, Patricia A., 598
Bryson, Scott M. (coauthor) see Leson, Cheryl L., 300
Bucaneve, Giampaolo (coauthor) see Del Favero, Albano, 45
Buener, Jon W. (author) Organic Nitrate-Induced Methemoglobinemia (A) 283
Bullock, Linda S. (author) Stability of Famotidine in Minibags Refrigerated and/or Frozen (RPR) 132; (author) Stability of Famotidine in Minibags Refrigerated and/or Frozen in Total Parenteral Nutrition Solutions (Oct) S44; (author) Stability of Intravenous Famotidine Stored in Polyvinyl Chloride Syringes (SR) 588
Burke, John M. (author) Calcium-Channel Blockers in Ischemic Heart Disease (DIAS) 245
Burks, Emalie J. (author) Nortrioxacin Hypersensitivity (L) 90
Burnakis, Thomas G. (author) Hostility and Hallucinations as a Consequence of Midazolam Administration (SR) 671
Burnette, Pearl K. (author) Rifampin-Associated Thrombocytopenia Secondary to Poor Compliance (CR) 382
Burton, Michael E. (author) Evaluation of a Bayesian Method for Predicting Vancomycin Dosing (RPR) 294
Buss, Renee L. (coauthor) see Tensley, Kathleen M., 411
Bussey, Henry L. (coauthor) see Mueller, Bruce A., 93
Bustack, James A. (coauthor) see Heizer, William D., 764

C

Cabezas, Ricardo (coauthor) see Torrent, Josep, 143
Calaresu, Pamela (coauthor) see Cersosimo, Robert J., 876
Cano, Manuel (coauthor) see Rodriguez, Carlos, 154
Canth, Thomas G. (author) Phenothiazines and Sudden Infant Death Syndrome (DIAS) 795
Cardona, Daniel (coauthor) see Gallastegui, Carmen, 1033
Cardoni, Alex A. (coauthor) see Fish, Susan S., 912
Carrigan, Thomas (coauthor) see Bader, Augustinus, 508
Carson, Stanley W. (author) Bupropion, Is It Here to Stay? (O) 704; (coauthor) see Karki, Shyam D., 372
Carter, Barry L. (author) Are You an Academician? (O) 920; (coauthor) see Noyes, Margaret A., 263
Carter, Charles A. (coauthor) see Hurwitz, Ar. th. (Oct) S10; (coauthor) see Schentag, Jerome J., (Oct) S36

- Caruso, Rocco F. (coauthor) see Hoffman, Dennis M., 157
 Casto, Daniel T. (coauthor) see Mueller, Bruce A., 93
 Cersosimo, Robert J. (author) Acute Hypotensive Reaction to Etoposide with Successful Rechallenge: Case Report and Review of the Literature (SR) 876; (coauthor) see Lesko, Anne B., 615
 Chabursky, Andrii (coauthor) see Sesin, G. Paul, 925
 Chan, Gary L.C. (coauthor) Alternative Dosing Strategy for Aminoglycosides: Impact on Efficacy, Nephrotoxicity, and Ototoxicity (TC) 788
 Chen, Bai H. (coauthor) see Ackerman, Bruce H., 375
 Chin, Alfred (author) Cost Analysis of Two Clindamycin Dosing Regimens (RPR) 980
 Chrischilles, Elizabeth A. (author) Effect of Clinical Pharmacy Services on the Quality of Family Practice Physician Prescribing and Medication Costs (PEC) 417
 Cluxton, Robert J., Jr. (author) book review, 817
 Cohen, Amos M. (author) Methazolamide-Associated Temporary Leukopenia and Thrombocytopenia (SR) 58
 Cohen, Louise Glassner (coauthor) see Fish, Susan S., 912
 Cold, Julie A. (coauthor) see Fromm, Sam H., 431
 Colome, Esteve (coauthor) see Rodriguez, Carlos, 154
 Colomina, Pedro (author) Agranulocytosis Caused by Diclofenac (L) 507
 Colvin, Carol L. (coauthor) see Alexander, Michael R., 214
 Conner, Joyce B. (author) Possible Fentanyl-Induced Thrombocytopenia (L) 507
 Contandriopoulos, Andre-Pierre (coauthor) see Laurier, Claudine, 862
 Cooper, James W. (coauthor) see Mallet, Louise, 63; (coauthor) see Morton, Mark R., 668
 Cope, Alan K. (author) The Search: Postgraduate Training and Beyond (L) 342
 Corelli, Robin (author) Beta-Blockers Agents for Migraine (DIAS) 248
 Costa, Jerome F. (coauthor) see Tran-Johnson, Tram, 1034
 Cox, Jennifer M. (author) Beclomethasone Dipropionate in Chronic Asthma (DIAS) 37
 Coyle, James D. (author) An Interim Perspective on the Removal of Enalapril and Flecainide from the Cardiac Arrhythmia Suppression Trial (O) 478
 Crismon, M. Lynn (author) Authors' Reply: Chlorpromazine Sudden Death (L) 512
 Crist, Kenneth D. (coauthor) see Grasele, Thaddeus H., Jr., 162
 Cronin, Simon M. (coauthor) see Garrick, Cindy L., 798
 Cuddy, Paul G. (coauthor) see Oki, Julie C., 399
 Curry, Stephen H. (author) Authors' Reply: Levotyrosine Bioequivalence (L) 813
- D**
- D'Angio, Richard G. (author) Time to Steady State Following a Change in Dosing Rate (TM) 468
 Darling, Inger M. (coauthor) see Wooding-Scott, Ronald A., 999
 Das, S.K. (coauthor) see Sarkar, P.K., 175
 Dasta, Joseph F. (coauthor) see Perkins, Mark W., 316, 757; (editor) Critical Care Therapeutics, 203, 316, 363, 757
 Davidson, Cheryl L. (coauthor) see Doering, Paul L., 639
 Davis, Hayes H. (coauthor) see Haug, Marcus T., III, 922
 Davis, Steven M. (coauthor) see Roents, Stan B., 235
 Davis, T. Allen (author) Orthostatic Hypotension: Therapeutic Alternatives for Geriatric Patients (G) 750
 Dawling, Sheila (author) Comment: Chlorpromazine Sudden Death (L) 510
 Dawson, Peter M. (author) Cardiac Dysrhythmia with the Use of Clonidine in Explosive Disorder (SR) 465
 Day, Robert G. (author) Comment: Clonidine in Nicotine Withdrawal (L) 1035
 de Gatta, M. Mar Fernandez (author) Predictive Techniques: Applied to Imipramine Therapeutic Drug Monitoring (TM) 389
 Delaven, Bryan (coauthor) see Perkins, Mark W., 316
 Delafuente, Jeffrey C. (coauthor) see Davis, T. Allen, 750
 De Lap, Robert J. (coauthor) see De Vito, Joseph M., 153
 Del Favero, Albano (author) Leukopenia with Neutropenia Associated with Teicoplanin Therapy (CR) 45
 DeMeester, Tom R. (coauthor) see Nwakama, Patrick E., 227
 Derry, John E. (coauthor) see Bartle, William R., 509
 Destache, Christopher J. (author) Author's Reply: Impact of a Kinetic Service on Aminoglycoside Patients (L) 622; (author) Impact of a Clinical Pharmacokinetic Service on Patients Treated with Aminoglycosides for Gram-Negative Infections (RPR) 33
 De Tullio, Pamela L. (author) Author's Reply: Long-Term Triazolam Use (L) 814; (author) Evaluation of Long-Term Triazolam Use in an Ambulatory Veterans Administration Medical Center Population (RPR) 290
 De Vito, Joseph M. (author) Bioequivalence of Two Leucovorin Calcium Tablet Formulations (SR) 153
 Dezziel-Evans, Lisa M. (author) Possible Sulfite Sensitivity with Gentamicin Infusion (L) 1032
 Diamond, Shelley A. (author) Contact Lens Damage Due to Ribavirin Exposure (L) 428
 Diaz, Fernando G. (coauthor) see Fagan, Susan C., 238
 Doering, Paul L. (author) book review, 95; (author) Effects of Cocaine on the Human Fetus: A Review of Clinical Studies (L) 639
 Doluisio, James T. (author) Positioning Pharmacy for the 21st Century (Rio Chi) 706
 Dominguez-Gil, Alfonso (coauthor) see de Gatta, M. Mar Fernandez, 389
 Donegan, Sarah (author) An Unusual Reaction to Etoposide (L) 177
 Dorn, Peter G. (coauthor) see Crismon, M. Lynn, 512
 Dozier, Nicky (coauthor) see Huber, Steve, (DIAS) 513
 Drea, Edward J. (author) Contrast Media Adverse Reactions (L) 925
 Driscoll, David F. (author) Drug-Induced Metabolic Disorders and Parenteral Nutrition in the Intensive Care Unit: A Pharmaceutical and Metabolic Perspective (CC) 363
 Druckenbrod, Richard W. (author) Iofetamine Hydrochloride

- 1123: A New Radiopharmaceutical for Cerebral Perfusion Imaging (FF) 19
 Dudley, Michael N. (author) Serum Inhibitory and Bactericidal Activity of Ciprofloxacin Following Intravenous Administration (RPR) 456
 Dukes, George E. (coauthor) see Hussey, Elizabeth K., 675
 Dupuis, Laura Lee (coauthor) see Diamond, Shelley A., 428
 Durrell, Diane E. (coauthor) see Nakata, Millap C., 466

E-F

- Eckhauser, Frederic E. (coauthor) see Alexander, Michael R., 214
 Edmunds, Ann L. (coauthor) see Miwa, Linda J., 773
 Edwards, David J. (author) book review, 263
 Ehresman, David J. (coauthor) see Graves, Nina M., 565
 Einarson, Thomas R. (author) Comment: Geriatric Patients' Functional Abilities (L) 513; (coauthor) see Gryfe-Becker, Brenda M., 324
 Ellsworth, Allan J. (author) Disopyramide and N-Monodesalkyl Disopyramide in Serum and Breast Milk (SR) 56
 Eron, Lawrence J. (author) Trial Using Early Preoperative Administration of Cefonicid for Antimicrobial Prophylaxis with Hysterectomy (RPR) 655
 Erramouse, John (author) Impact of Education by Clinical Pharmacists on Physician Ambulatory-Care Prescribing of Generic Versus Brand-Name Drugs (RPR) 770
 Erstad, Brian L. (author) Severe Cardiovascular Adverse Effects in Association with Acute, High-Dose Corticosteroid Administration (DIR) 1019
 Evans, John (coauthor) see Comer, Joyce B., 507
 Eward, Ann M. (author) book review, 719
 Fagan, Susan C. (author) Hemodynamic Vertebral Basilar Insufficiency as an Adverse Effect of Antihypertensive Therapy (SR) 238; (author) Risk of Cerebral Hypoperfusion with Antihypertensive Therapy (A) 957
 Farah, Michel G. (coauthor) see Bednarczyk, Edward M., 869
 Fazio, Anthony (coauthor) see Henann, Neil E., 430
 Fernandez, Rafael (coauthor) see Trigrine, Carlos, 923
 Fields, Suzanne M. (author) Thrombotic Microangiopathy Associated with Chemotherapy: Case Report and Review of the Literature (CR) 582
 Finley, Patrick R. (author) Precipitation of Benzodiazepine Withdrawal Following Sudden Discontinuation of Midazolam (SR) 151
 Finley, Rebecca S. (author) book review, 1037
 Fish, Susan S. (author) Clinical Pharmacy Education in New England: A Report of the Whispering Pines Conference (ET) 912
 Fitch, Duane D. (coauthor) see Heizer, William D., 764
 Fitzgerald, Joseph F. (coauthor) see Bullock, Linda S., 132, 588
 Fletcher, Courtney V. (author) Evaluation of Ganciclovir for Cytomegalovirus Disease (ID) 5
 Forbes, William P. (coauthor) see Hilleman, Daniel E., 357
 Foster, Thomas S. (coauthor) see Rapp, Robert P., 899
 Francis, George C. (author) Authors' Reply: Muronob CD3 Aseptic Meningitis (L) 716; (coauthor) see Sutton, Jacqueline D., 257
 Francis, Valerie L. (coauthor) see Steele, Malcolm A., 497
 Fredrick, Dean A. (author) Comment: TMP/SMX-Warfarin Interaction (L) 619
 Fretwell, Marsha D. (coauthor) see Owens, Norma J., 347
 Frisole, Julie A. (author) Continuous Verapamil Infusion? (DIAS) 1005
 Fromm, Sam H. (author) Pharmacoeconomic Evaluations in Medicine (L) 431
 Fuchs, John E., Jr. (author) Probable Metolazone-Induced Pancreatitis (L) 711
 Fuerst, Robin H. (author) Tocolin in Myotonic Dystrophy (DIAS) 69; (coauthor) see Hamel, Harvey J., 71
 Fus, Andrea S. (coauthor) see Plessants, Roy A., 460

G

- Gagnon, Antony (author) Colchicine in Liver Cirrhosis (DIAS) 388
 Gal, Peter (coauthor) see Kandrotas, Robert J., 137
 Galanos, Anthony N. (coauthor) see Fuchs, John E., Jr., 711
 Gallastegi, Carmen (author) Vitamin B₁₂-Induced Folliculitis (L) 1033
 Gallelli, Joseph F. (author) book review, 1037
 Garcia, Benito (coauthor) see Gallastegi, Carmen, 1033
 Garcia, Maria Jose (coauthor) see de Gatta, M. Mar Fernandez, 389
 Garcia, Sonia (coauthor) see Colomina, Pedro, 507
 Garcia-Bragado, Fernando (coauthor) see Rivera, Jose M., 811
 Gardner, Stephanie F. (coauthor) see Himmelberg, Cheryl J., 509
 Garrick, Cindy L. (author) Effect of Mesna on Cyclophosphamide (DIAS) 798
 Gelb, Adrian W. (coauthor) see Meeks, Rodney L., 579
 Gelfand, Michael J. (coauthor) see Druckenbrod, Richard W., 19
 Geltner, David (coauthor) see Malnick, Stephen D.H., 811
 Gentile, Donald L. (coauthor) see Burton, Michael E., 294
 Gerick, Kristin R. (author) Dinoprost in Hemorrhagic Cystitis (DIAS) 885
 Gibson, Steven M. (coauthor) see Morrill, Gregory B., 90
 Giesbrecht, Esther E. (coauthor) see Leson, Cheryl L., 300
 Gill, Mark A. (coauthor) see Chin, Alfred, 980
 Glick, Melvin R. (coauthor) see Bullock, Linda S., 132
 Goldenherb, Michael (coauthor) see Oren, Ran, 88
 Gonzalez, Edgar R. (author) Reducing the Risk of Aspiration Pneumonitis (CC) 203
 Goodale, Elizabeth P. (author) Pediatric Bowel Evacuation with a Polyethylene Glycol and Iso-osmolar Electrolyte Solution (DIAS) 1008
 Gopalswamy, N. (coauthor) see Bader, Augustinus, 508
 Gordon, Steven F. (coauthor) see Eron, Lawrence J., 655

- Gorman, Richard L. (coauthor) see Vuignier, Barbara Inley, 26
 Goyan, Jere E. (author) Author's Reply: Pharmacy Education and Its Impact on Practice (L) 260
 Grabenstein, John D. (author) Comment: Pneumococcal Revaccination (L) 258
 Graber, Stanley E. (coauthor) see Steele, Malcolm A., 497
 Grasele, Thaddeus H., Jr. (author) A Clinical Pharmacy-Oriented Drug Surveillance Network: Results of a Nationwide Antibiotic Utilization Review of Bacterial Pneumonia—1987 (PEP) 162
 Gratz, Irwin (coauthor) see Larjani, Ghassam E., 743
 Graves, Nina M. (author) Relative Bioavailability of Rectally Administered Phenobarbital Sodium Parenteral Solution (RPR) 565
 Green, Jeffrey A. (coauthor) see Bednarczyk, Edward M., 869
 Grilo, Antonio (coauthor) see Rivera, Jose M., 811
 Grimm, Aileen M. (author) Aseptic Meningitis Associated with Nonprescription Ibuprofen Use (L) 712
 Gryfe-Becker, Brenda M. (author) Effect of Auxiliary Prescription Labels on the Elderly Ambulatory Patient's Drug Knowledge (G) 324
 Guay, David R.P. (author) Cost Comparison of Ciprofloxacin Versus Cefamandole (L) 92
 Gundlach, Catherine (coauthor) see Fish, Susan S., 912
 Gusenko, Linda A. (coauthor) see Valida, Allen J., 379
 Gutierrez, J. Ramon (coauthor) see de Gatta, M. Mar Fernandez, 389
 Gwill, Peter R. (coauthor) see D'Angio, Richard G., 468

H

- Haines, Kathryn A. (coauthor) see Washington, Carla, 713
 Hale, William E. (coauthor) see Stewart, Ronald R., 610
 Haley, Christopher J. (author) Phenytoin-Enteral Feeding Interaction (DIAS) 796
 Halperin, Itzhack (coauthor) see Heyman, Samuel N., 236
 Halperin, Jerome A. (author) Potassium Iodide as a Thyroid Blocker—Three Mile Island to Today (O) 422
 Halperin, Mordechai (coauthor) see Malnick, Stephen D.H., 811
 Halpern, Pinchas (coauthor) see Perkins, Mark W., 757
 Halstenson, Charles E. (coauthor) see Schwenk, Michael H., 528
 Hammond, Douglas (author) Theophylline Toxicity: Acute Illness, and Cefalor Administration (L) 339
 Hammond, John E. (coauthor) see Heizer, William D., 764
 Hanel, Harvey J. (author) Prevention of I¹³¹Iodine Ossification (DIAS) 71
 Harats, Noam (author) Cimetidine-Induced Thrombocytopenia in a Cirrhotic Patient (L) 177
 Harper, Karen J. (author) Malabsorption of Erythrosine in a Pediatric Patient with Schwachman Syndrome (SR) 782
 Hart, Linda L. (coauthor) see Corelli, Robin, 248; (coauthor) see Gerick, Kristin R., 885; (coauthor) see Lingle, Lisa, 246; (coauthor) see Maltzer, Bruce C., 307; (coauthor) see Pon, Doreen, 602; (coauthor) see Schott, William J., 308; (coauthor) see Zehnder, Robert, 402; (editor) DIAS Rounds, 69, 245, 307, 386, 473, 597, 687, 795, 880, 1005
 Hartshorn, Edward A. (editor) Drug Interactions and Reactions Update, 1019
 Harzema, Abraham G. (editor) Pharmacoeconomics, 162, 698, 800
 Harvey, Lisa (coauthor) see Eron, Lawrence J., 655
 Harvit, Pamela A. (author) book review, 719
 Hashimoto, Yoshimi (coauthor) see Shindo, Kunitoshi, 672
 Hatton, Jimmi (author) Estimation of Creatinine Clearance in Patients with Cushing's Syndrome (RPR) 974
 Haug, Marcus T., III (author) Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations (L) 922
 Hawkins, Allen (author) Comment: Stability of Caffeine Injection (L) 928
 Hecht, Lisa (author) Correction: Theophylline-Pyranol Pamoate Interaction (L) 432; (author) Theophylline-Pyranol Pamoate Interaction (L) 258
 Heh, Chris D. (coauthor) see Tran-Johnson, Tram, 1034
 Heizer, William D. (author) Absorption of Digoxin from Tablets and Capsules in Subjects with Malabsorption Syndromes (RPR) 764
 Helling, Dennis K. (coauthor) see Chrischilles, Elizabeth A., 417
 Hemstroom, Carl Arthur (author) Nutriance—For One, For All (L) 926
 Henann, Neil E. (author) Survey of Required Clinical Pharmacy Textbooks (L) 430
 Henderson, Robert P. (coauthor) see Burke, John M., 245
 Hennessey, Sean (coauthor) see Boyce, Eric G., 590
 Hermens, Walter J.H.H. (coauthor) see Janknegt, Robert, 91
 Herrera, John M. (coauthor) see Tran-Johnson, Tram, 1034
 Heseltine, Peter N.R. (coauthor) see Chin, Alfred, 980
 Heyman, Ayelet (coauthor) see Harats, Noam, 177; (coauthor) see Heyman, Samuel N., 236; (coauthor) see Oren, Ran, 88; (coauthor) see Rabinovitch, Reuben, 780
 Heyman, Samuel N. (author) Diabetogenic Effect of Nifedipine (SR) 236
 Higgins, James T. (coauthor) see Mauro, Laurie Slack, 64
 Hilleman, Daniel E. (author) Role of Milrinone in the Management of Congestive Heart Failure (FF) 357; (coauthor) see Bidde, Paul, 665; (coauthor) see Maltzer, Bruce C., 307; (coauthor) see Moos, Arvan N., 562
 Hilman, Bettina C. (coauthor) see Kearns, Gregory L., 1013
 Himmelberg, Cheryl J. (author) A Nursery Rhyme for Tick Time (L) 509
 Hiner, William O. Jr. (coauthor) see Bjornson, Darrel C., 698
 Hippo, Thomas P. (coauthor) see Nakata, Millap C., 1033
 Hirota, Noritake (author) Does Theophylline Raise Serum Uric Acid Levels in Asthmatic Children? (L) 714
 Hoang, Vu (coauthor) see Burnette, Pearl K., 382
 Hoffman, Dennis M. (author) Human Immunodeficiency Virus-Associated Thrombocytopenia (TC) 157
 Holden, J.M.C. (coauthor) see Karki, Shyam D., 372
 Holmes, Gregory B. (coauthor) see Graves, Nina M., 565

- 1062 ■ DICP, The Annals of Pharmacotherapy ■ 1989 December, Volume 23

Oren, Ran (author) Nifedipine-Induced Nonthrombocytopenic Purpura (L) 88; (coauthor) see Harats, Noam, 177
 Ortmeier, Brian G. (coauthor) see Destache, Christopher J., 33
 Owens, Norma J. (author) The Relationship Between Comprehensive Functional Assessment and Optimal Pharmacotherapy in the Older Patient (G) 847
 Paap, Christopher M. (author) Clinical Use of Trimethoprim/Sulfamethoxazole During Renal Dysfunction (A) 646; (author) Comment: Muromonab CD3 Aseptic Meningitis (L) 718
 Padomek, Michael T. (coauthor) see Destache, Christopher J., 33
 Pan, C. Vidal (author) Topical Promethazine Intoxication (L) 89
 Paradiso, Frances L. (coauthor) see Bartle, William R., 509
 Parish, Roy C. (author) Comment: Phenytoin Equation Accuracy (L) 621; (author) Comparison of Linear Regression Methods When Both Variables Contain Error: Relation to Clinical Studies (CS) 891
 Parker, Robert B. (author) Propafenone: A Novel Type Ic Antiarrhythmic Agent (FF) 196
 Parr, Michael D. (coauthor) see Hutton, Jimmie, 974
 Patino, Lucio (coauthor) see Del Favero, Albano, 45
 Payne, Lance W. (coauthor) see Fagan, Susan C., 957
 Pelligrino, John (coauthor) see Nwakama, Patrick E., 227
 Perkins, Mark W. (author) Intraoperative Complications in Patients Receiving Amiodarone: Characteristics and Risk Factors (CT) 757; (author) Physiologic Implications of Mechanical Ventilation on Pharmacokinetics (CT) 316
 Perri-L-Francesca, Joanne (coauthor) see Baptista, Richard J., 59
 Peterson, Charles D. (coauthor) see Lake, Kathleen D., 618
 Peterson, Philip K. (coauthor) see Guay, David R.P., 92
 Petty, Daniel E. (coauthor) see Siepler, John K., (Oct) 540
 Phifer, William (coauthor) see Burnette, Pearl K., 382
 Pilla, Alison M. (coauthor) see Zarowitz, Barbara J., 548
 Pilley, Gerard (author) Fish Oil Controversy (L) 92
 Pirchard, Thomas J. (coauthor) see Neme, Mary Alice, 128
 Pittman, A. Wayne (coauthor) see Heizer, William D., 764
 Pleasants, Roy A. (author) Tobramycin Administration and Blood Sampling Through a Dual-Lumen Peripheral Intravenous Catheter (RPR) 460; (coauthor) see Williams, Dennis M., 815
 Plumridge, Richard J. (author) Drug Bulletins: Effectiveness in Modifying Prescribing and Methods of Improving Impact (IR) 330
 Polak, Arthur (coauthor) see Oren, Ran, 88
 Polk, William H. (coauthor) see Koestner, James A., 48
 Pon, Doreen (author) IV Lidocaine as an Analgesic (DIAS) 602
 Ponte, Charles D. (author) Estrogen Replacement Therapy: A Pilot Survey of Primary Care Physicians in West Virginia (RPR) 977; (author) Heinz-Body Hemolytic Anemia Associated with Phenazopyridine and Sulfonamide (CR) 140
 Porta, Miguel S. (coauthor) see Hartzema, Abraham G., 162, 698, 800
 Present, Daniel H. (coauthor) see Sottile, Roseann F., 963
 Priatnik, Michael (coauthor) see Cohen, Amos M., 58
 Priebe, Maude H. (coauthor) see Francos, George C., 716; (coauthor) see Sutton, Jacqueline D., 257
 Priks, Susan C. (author) book review, 96, 181; (coauthor) see Nelhouse, Paul F., 594
 Provost, Pamela S. (coauthor) see Segin, G. Paul, 812
 Pujol, Ramon (coauthor) see Gallastegui, Carmen, 1033
 Purdy, Caryn Yoder (coauthor) see Jones, James B., 88

Q-R

Quandt, Christine M. (coauthor) see Sottile, Roseann F., 963
 Quintana, A. Gonzalez (coauthor) see Pan, C. Vidal, 89
 Quintillani, Richard (coauthor) see Smith, Karen S., 1024
 Rabinovici, Reuben (coauthor) see Shindo, Kunihiko, 720
 Radandt, Joan M. (author) The Role of Aerosolized Pentamidine in Management of HIV-Related *Pneumocystis carinii* Pulmonary Infections (O) 806
 Raebel, Marsha A. (coauthor) see Thompson, Dennis F., 675, 788, 995
 Raisis, Vidmantas A. (coauthor) see Ellsworth, Allan J., 56
 Raleigh, Fred R. (author) Buspirone: A Potential for Abuse? (L) 1032
 Rapp, Robert P. (author) Parenteral Nutrition: 1989 and Beyond (E) 703; (author) Patient-Controlled Analgesia: A Review of Effectiveness of Therapy and an Evaluation of Currently Available Devices (A) 899
 Raynor, Stephen C. (coauthor) see Miwa, Linda J., 773
 Recker, David P. (author) Successful Prevention of an Anaphylactoid Reaction to High-Dose Methotrexate (L) 1032
 Reed, Michael D. (author) Developmental Pharmacology: Relationship to Drug Use (J/A) S21; (editor) Pediatrics, 1013
 Reents, Stan B. (author) Phenytoin-Carbamazepine Cross-Sensitivity (SR) 235
 Reilly, Thomas E. (coauthor) see Perkins, Mark W., 757
 Reinsmith, William A. (coauthor) see Boyce, Eric G., 590
 Rello, Jordi (coauthor) see Triguera, Carlos, 923
 Rey, Francisco (coauthor) see de Gatta, M. Mar Fernandez, 389
 Riger, Bruce (coauthor) see Mason, Barb, 711
 Rivera, Jose M. (author) Possible Estrogen-Induced NMS (L) 811
 Rivey, Michael P. (author) TMP/SMX in Renally Impaired Patients with *P. carinii* Pneumonia (DIAS) 687
 Robinson, Dennis H. (author) book review, 929
 Robinson, J. Daniel (editor) Therapeutic Monitoring, 64, 240, 389, 468, 999
 Rocci, Mario L., Jr. (coauthor) see McCrea, Jacqueline B., 38
 Rodriguez, Carlos (author) Evaluation of Cefonicid Use in a General Hospital (SR) 154
 Rodvold, Keith A. (coauthor) see Shwed, Jill A., 70
 Rogers, John S., II (coauthor) see Ponte, Charles D., 140
 Rovang, Karen S. (coauthor) see Malesker, Mark A., 855
 Rowden, Annette M. (author) Codeine Addiction (DIAS) 475; (author) Prazosin in Benign Prostatic Hypertrophy (DIAS) 474
 Rozek, Susan L. (coauthor) see Gagnon, Anthony, 388
 Rubenstein, Stuart (coauthor) see Hecht, Lisa, 258
 Rybak, Michael J. (coauthor) see Smythe, Maureen A., 839

S

Salgado, Vicente (coauthor) see Rivera, Jose M., 811
 Sarkar, P.K. (author) Practitioners' Obligations: To the Public or the Drug Industry? (IR) 175
 Saunders, E. Fred (coauthor) see Leson, Cheryl L., 300
 Savanokot, Uthai (coauthor) see Kanjaram, Seng, 29
 Savir, Hanna (coauthor) see Cohen, Amos M., 58
 Saviola, Mohammed (coauthor) see Ludwig, Elizabeth A., 858
 Sawyer, William T. (author) Author's Reply: TMP/SMX-Warfarin Interaction (L) 620; (coauthor) see Harper, Karen J., 782
 Sawyers, John L. (coauthor) see Koestner, James A., 48
 Scarim, Sheila K. (author) Treatment of Doxorubicin Extravasations (DIAS) 386
 Schaaf, Stephen F. (coauthor) see Coyle, James D., 478
 Scheiffe, Richard T. (author) Protein Binding: What Does It Mean? (J/A) S27
 Schentag, Jerome J. (author) Safety and Acid-Suppressant Properties of Histamine-2 Receptor Antagonists for the Prevention of Stress-Related Mucosal Damage in Critical Care Patients (Oct) 536; (coauthor) see Graseila, Thaddeus H., Jr., 162
 Schifano, Fabrizio (author) Long-Term Attacks and Major Depression After Discontinuation of Panic-Attack Diazepam Abuse (SR) 989
 Schott, William J. (author) Drug Treatment for Sleep Apnea (DIAS) 308
 Schrouff, Gabriel G.M. (coauthor) see Janknegt, Robert, 91
 Schuna, Arthur A. (coauthor) see Meyer, Maren E., 171, 513
 Schwartz, Arthur (author) Potential Aspirin-Related Drug Interactions in the Elderly (L) 340
 Schwenk, Michael H. (author) Recombinant Human Erythropoietin (FF) 528
 Segal, Harold J. (coauthor) see Gryfe-Becker, Brenda M., 324
 Seifert, Charles F. (author) Intravenous Erythromycin Lactobionate-Induced Severe Nausea and Vomiting (CR) 40
 Seligman, Marissa (author) Comment: Nimodipine in Treatment of Subarachnoid Hemorrhage (L) 927
 Sensenbrenner, Lyle L. (coauthor) see Garrick, Cindy L., 798
 Seoka, Sybil N.E. (coauthor) see Schwartz, Arthur, 340
 Segin, G. Paul (author) Cost of Liver Transplant Treatment (L) 925; (author) Influencing Parenteral Histamine-2 Receptor Antagonist Use (L) 812; (coauthor) see Lesko, Anne B., 615
 Shafer, Mark S. (coauthor) see Miwa, Linda J., 773
 Shapiro, Steven A. (coauthor) see Valida, Allen J., 379
 Sherlock, Susan C. (coauthor) see Bednarczyk, Edward M., 869
 Shimp, Leslie A. (author) Ranitidine-Induced Chest Pain (CR) 224
 Shinar, Elliot (coauthor) see Rabinovici, Reuben, 780
 Shindo, Kunihiko (author) Granulocytopenia and Thrombocytopenia Associated with Combination Therapy of Amphotericin B and Low-Dose Flucytosine in a Patient with Cryptococcal Meningitis (SR) 672
 Shionoiri, Hiroaki (coauthor) see Shindo, Kunihiko, 672
 Shwed, Jill A. (author) Anion-Exchange Resins and Oral Vancomycin in Pseudomembranous Colitis (DIAS) 70
 Siepler, John K. (author) Use of Continuous Infusion of Histamine-2 Receptor Antagonists in Critically Ill Patients (Oct) 540
 Siliman, Rebecca S. (coauthor) see Owens, Norma J., 847
 Simon, Deborah L. (author) Comment: Doxorubicin Extravasations (L) 928
 Sites, James (coauthor) see Eron, Lawrence J., 655
 Sklar, Michael H., Sr. (coauthor) see Malesker, Mark A., 855; (coauthor) see Mooss, Aryan N., 562
 Sklar, Garry S. (author) Therapeutic-Sparing Properties of Butorphanol/Diazepam for Induction of Anesthesia in Ambulatory Gynecologic Surgery (RPR) 659
 Skoutakis, Vasiliou A. (author) Comparison of the Parenteral Histamine-2 Receptor Antagonists (Oct) S17; (author) Introduction: Aims of the Symposium (Oct) S9; (coauthor) see Nully, Robert J., S23
 Slack, Marion K. (author) Comment: Undergraduate Education (L) 715
 Slaughter, Richard L. (author) book review, 433; (author) Probability Assessment Approach to Therapeutic Drug Monitoring: Tobramycin (TM) 240; (coauthor) see Babul, Najib, 713; (coauthor) see Ludwig, Elizabeth A., 858; (coauthor) see Wooding-Scott, Ronald A., 999
 Smith, Dorothy L. (coauthor) see Levy, Richard A., 76, 432
 Smith, Karen S. (author) Formulary Conversion of Cefotaxime Usage to Cefotetan: Experience at a Large Teaching Hospital (PEC) 1024
 Smith, Mindy A. (coauthor) see Shimp, Leslie A., 224
 Smythe, Maureen A. (author) Ofloxacin: A Review (FF) 839; (author) Phenytoin Hepatotoxicity: A Review of the Literature (A) 13
 Soifer, Betsy E. (coauthor) see Meeks, Rodney L., 579
 Sonn, David Dae-Ik (coauthor) see Sklar, Garry S., 659
 Sorrells, Susan C. (coauthor) see Neme, Mary Alice, 128
 Sottile, Roseann F. (author) Medical Management of Inflammatory Bowel Disease (A) 963
 Souney, Paul F. (author) Pharmacoeconomic Aspects and Formulary Considerations Related to Histamine-2 Receptor Antagonists (Oct) S29
 Sramek, John J. (coauthor) see Tran-Johnson, Tram, 1034
 Steele, Malcolm A. (author) Cost-Effectiveness of Two Interventions for Reducing Outpatient Prescribing Costs (PEC) 497
 Stein, Daniel J. (coauthor) see Guay, David R.P., 92
 Stewart, Ronald B. (author) Changing Patterns of Psychotropic Drug Use in the Elderly: A Five-Year Update (G) 610; (author) Nutritional Supplements in the Ambulatory Elderly Population: Patterns of Use and Requirements (G) 490; (coauthor) see Ware, Michael R., 428; (editor) Geriatrics and Gerontology, 171, 324, 490, 610, 75, 847
 Stoukides, Cheryl A. (coauthor) see Souney, Paul F., (Oct) S29
 Stringer, Kathleen A. (coauthor) see Tisdale, James E., 984
 Strozky, William R. (coauthor) see McKenzie, Constance A., 1038
 Stumpf, Janice L. (coauthor) see Alexander, Michael R., 214
 Sue, Doris (coauthor) see Lee, Benny, 691
 Sumner, Edward D. (author) book review, 181

Sutton, Jacqueline D. (author) Aseptic Meningitis Associated with Muromonab CD3 Administration (L) 257; (coauthor) see Francos, George C., 716
 Swaney, R. Jan (coauthor) see Seifert, Charles F., 40
 Swinker, Marian L. (coauthor) see Ponte, Charles D., 977

T

Talbert, Robert L. (coauthor) see Neme, Mary Alice, 128
 Tam, Carlos W. (coauthor) see Washington, Carla, 713
 Tamayo, Milagros (coauthor) see de Gatta, M. Mar Fernandez, 389
 Tartaglione, Teresa A. (author) Choosing Cephalosporins for the Formulary (J/A) S8; (coauthor) see Radandt, Joan M., 806
 Taylor, E. Howard (coauthor) see Ackerman, Bruce H., 375
 Taylor, Jerry W. (coauthor) see Rivey, Michael P., 687
 Teasley, Kathleen M. (author) Do Parenteral Nutrition Solutions with High Concentrations of Branched-Chain Amino Acids Offer Significant Benefits to Stressed Patients? (TC) 411
 Theisen, Karen A. (author) Relief of Diabetic Neuropathy with Fluoxetine (CR) 572
 Thomas, Joyce (coauthor) see Mallet, Louise, 63
 Thompson, Dennis F. (author) Comment: Additional Foreign Drug Identification (L) 815; (author) Neuromuscular Blocking Agents in Burn Patients (DIAS) 1006; (editor) Therapeutic Controversies, 675, 788, 995
 Thrasher, Kimberly A. (coauthor) see Fish, Susan S., 912
 Tietze, Karen J. (coauthor) see Yasuda, Sally Udlin, 651, 927
 Tilson, Hugh H. (coauthor) see Harzema, Abraham G., 498, 800
 Timm, Edward G. (author) Cimetidine in Malignant Melanoma (DIAS) 689
 Tisdale, James E. (author) Streptokinase-Induced Anaphylaxis (CR) 984
 Torrent, Josep (author) Theophylline-Isoniazid Interaction (CR) 143
 Townsend, Raymond J. (coauthor) see Bootman, L. Lyle, 693; (coauthor) see McGhan, William F., 417, 497, 693, 1024
 Tramont, Edmund C. (coauthor) see Bjorsson, Darrel C., 698
 Tran-Johnson, Tram (author) Effects of Carbamazepine on Serum Calcium in Schizophrenia (L) 1034
 Treeman, Christopher M. (author) Comment: Pharmacist Contribution to IRB (L) 816
 Trisner, Charles (author) Gentamicin Pharmacokinetic Changes Related to Mechanical Ventilation (L) 923
 Trudeau, Walter (coauthor) see Siepler, John K., (Oct) 540
 Trulsch, Dietmar V. (coauthor) see Bader, Augustinus, 508
 Tuma, Thomas A. (coauthor) see Dawson, Peter M., 465

U-Z

Uemoto, Kiyotaka (coauthor) see Ueno, Kazuyuki, 662
 Ueno, Kazuyuki (author) Effect of Food on Nifedipine Sustained-Release Preparation (RPR) 662
 Ujhelyi, Michael R. (author) Author's Reply: Unusual Digoxin Concentrations (L) 94, 717
 Umstead, Greg S. (coauthor) see Smythe, Maureen A., 13
 Valida, Allen J. (author) Use of an Ambulatory Infusion Pump in a 12-Year-Old with *Salmonella* Osteomyelitis (CR) 379
 Vander Zanden, Jeanne A. (coauthor) see Dawson, Peter M., 465
 VanRiper, Kurt (coauthor) see Madrazo, Glenn, 341
 Vasko, Michael R. (coauthor) see Burton, Michael E., 294
 Vaughan, Leigh M. (author) Correction: SI Units in Drug Therapeutics (L) 262
 Vic, J. Mateo (coauthor) see Pan, C. Vidal, 89
 Viessas, Peter H. (author) Pharmacist Contribution to the IRB (L) 431; (coauthor) see Kosoglou, Teddy, 116; (coauthor) see McCrea, Jacqueline B., 38
 Vuignier, Barbara Insley (author) Effects of Magnesium Citrate and Cidilium Bromide on the Excretion of Activated Charcoal in Normal Subjects (RPR) 26
 Wada, Kyuichi (coauthor) see Ueno, Kazuyuki, 662
 Wagner, Richard L. (coauthor) see Bablenis, Elena, 109
 Wahr, Dennis W. (coauthor) see Shimp, Leslie A., 224
 Walker, Neal R. (coauthor) see Tran-Johnson, Tram, 1034
 Walmer, William E. (coauthor) see Pleasants, Roy A., 460
 Ware, Michael R. (author) Seizures Associated with Fluoxetine Therapy (L) 428
 Washington, Carla (author) Amoxapine-Induced Neuroleptic Malignant Syndrome (L) 713
 Washington, Reginald L. (coauthor) see Dawson, Peter M., 465
 Watson, William A. (coauthor) see Blum, Robert A., 74; (coauthor) see Sklar, Garry S., 659; (coauthor) see Vuignier, Barbara Insley, 26; (coauthor) see Yudefreund, Shari M., 614
 Wayne, Lawrence A. (author) Comment: Ethylene Glycol Toxicity (L) 432
 Weber, Stanley S. (coauthor) see Bablenis, Elena, 109
 Weiss, Arnold L. (coauthor) see De Vito, Joseph M., 153
 Welage, Lynda S. (coauthor) see Schentag, Jerome J., (Oct) S36
 Wells, Barbara G. (author) Bromocriptine in Treatment of Depression (DIAS) 600; (coauthor) see Froemming, Sam H., 431; (coauthor) see Marken, Patricia A., 598
 Welty, Timothy E. (author) The Need for a Spiritual Dimension in Pharmacy Education (O) 337
 Werkman, Sidney L. (coauthor) see Dawson, Peter M., 465
 Whitney, Harvey A.K. (author) *The Annals of Pharmacotherapy*—More Than a Face Lift (E) 73
 Widdop, Brian (coauthor) see Dawling, Sheila, 510
 Williams, Charles A. (coauthor) see Doring, Paul L., 639
 Williams, Craig C. (coauthor) see Druckenbrod, Richard W., 19
 Williams, Dennis M. (author) Comment: Metered-Dose Inhalers (L) 815; (coauthor) see Pleasants, Roy A., 460
 Williams, W. Donald (coauthor) see Julius, Heare Chung, 568
 Wilson, Frederick S. (author) Comment: NSAID Substitution (L) 432
 Wilson, John T. (coauthor) see Berg, Jeffrey A., 812; (coauthor) see Kearns, Gregory L., 1013

Windle, Mary L. (coauthor) see Miwa, Linda J., 615
 Wiser, Thomas A. (author) book review, 180
 Wolf, Judith E. (coauthor) see Grimm, Aileen M., 712
 Wolfson, Bernard B. (coauthor) see Curry, Stephen H., 813
 Wooding-Scott, Ronald A. (author) Comparison of Assay Procedures Used to Measure Total and Unbound Concentrations of Quinidine (TM) 999
 Wordell, Cindy J. (coauthor) see Franco, George C., 716; (coauthor) see Sutton, Jacqueline D., 257
 Yamawaki, Hitoshi (coauthor) see Hirota, Noritake, 714
 Yamazaki, Kunio (coauthor) see Ueno, Kazuyuki, 662
 Yasuda, Sally Usdin (author) Authors' Reply: Nimodipine in Treatment of Subarachnoid Hemorrhage (L) 927; (author) Nimodipine in the Treatment of Subarachnoid Hemorrhage (FF) 451
 Yellin, Albert E. (coauthor) see Chin, Alfred, 980
 Yudenfreund, Shari M. (author) pH-Buffered 2-Chloroprocaine for Intravenous Regional Anesthesia (L) 614
 Zacardelli, Debra K. (coauthor) see De Tullio, Pamela L., 290
 Zarowitz, Barbara J. (author) Bioelectrical Impedance in Clinical Practice (A) 548
 Zehnder, Robert (author) Nonoxonyl 9 in Herpes (DIAS) 462
 Zingarelli, Josephine R. (coauthor) see Nahata, Milap C., 466, 1035
 Zimmer, Stephen H. (coauthor) see Dudley, Michael N., 456

ADVERTISER INDEX

Abbott Diagnostics, Abbotase Pharmacokinetics System, 231, 395, 575, 727
 American Society of Hospital Pharmacists, International Pharmaceutical Abstracts, 230, 680, 834
 Bristol Laboratories, Paraplatin, ifc-S, ifc-N; VePesid, ifc-F Centocor, A new breed of pharmaceuticals, 636, 740, 936
 Drug Usage Evaluation, DUE Manual, 87, 188, 255, 352
 Eli Lilly, Keturox, Tazidime, 732, 828, 946, 1044; Lilly information bank, 724
 Genentech, Inc., Activase, btw 592-594, btw 680-682, btw 776-778, 825, 837, 955
 Glaxo Inc., Fortaz, Zinacef, Cefitin, obc-Ja, obc-F, obc-Ma, obc-Ap, obc-M, obc-Je, obc-JA, obc-S, obc-O, obc-N, obc-Dec; Zantac, 484
 Harvey Whitney Books, A Casebook in Social and Behavioral Pharmacy, 170, 217, 329, 416, 489, 578, 702, 952; CA/CTF, subscription information, 188, 265, 349, 356, 444, 519, 561, 679, 787, 943, ifc-Dec; DICI, back issues, 272, 427, 581, 697, 810, 898, 1020, subscription information, 2, 106, 194, 274, 354, 442, 525, 634, 742, 836, 954; DRUGCALC, 710, 830, 868, 998; Drug Therapy and Pharmacy Books and Reprints, 80, 161, 256, 336, 409, 496, 616; Drug Therapy and Pharmacy Books, Journals, and Reprints, 682, 822, 1050; Fax reprint service, 763, 911, 1023; Guidelines for the Administration of Commonly Used Intravenous Drugs, 87, 146, 255, 293, 362, 506, 756, 938, 973; Journal of Pharmacy Technology, subscription information, 147, 604, 779, 1048; KINPAK, 54, 150, 344; Medical Abbreviations, 190, 234, 314, 398, 482, 738, 990; 1989 Administration Guidelines for Parenteral Drug Therapy, 527, 638, 820, 887, 1049; PharmACE, 98, 108, 266, 345, 483, 592, 723, 805, 854, 1042; Pharmacoeconomics: An Introduction, 24, 182, 264, 282, 371; Pharmacokinetics and Pharmacodynamics: Current Problems, Potential Solutions, 24, 135, 208, 303, 394, 472, 536, 670, 794, 875, 1012; Pharmacokinetics and Pharmacodynamics: Research Design and Analysis, 145, 229, 288, 394, 472, 536, 670, 794, 875, 979; PICA, subscription information, 176, 253, 338, 410, 495, 718, 816, 962; Psychotropic Drug Handbook, 12, 122, 202, 323, 477, 609, 686, 786, 886, 1034
 Lederle Laboratories, Pipracil, ifc-Ja, ifc-Ma, ifc-My, ifc-JA, ifc-O, ifc-Dec
 Mead Johnson Oncology Products, Ifex, ifc-Ap, ifc-Je
 Personnel Placement, Arizona, Scottsdale Memorial Health Systems, Inc., 438; California, Pharmacists' Letter, 188, Amgen, Inc., 734, Brookside Hospital, 628, OPTION Care, 348, 438, 517, University of the Pacific, 270; Canada, Drugs Directorate of Health and Welfare Canada, 729, University of Alberta, 728; Colorado, Swedish Medical Center, 437, 518; Delaware, Kent General Hospital, 186; Florida, Florida Hospital Medical Center, 629, Southeastern College of Pharmacy, 728, St. Joseph's, 519, Tampa General Hospital, 630, University of Florida, 270, 627, University of Miami/Jackson Memorial Hospital, 628; Idaho, Idaho State University, 103, 824, 944; Illinois, Christ Hospital & Medical Center, 187, Ravenswood Hospital Medical Center, 942, University of Illinois at Chicago, 734; Indiana, Quad Pharmaceuticals, Inc., 517; Iowa, Mercy Health Center, 941, Mercy Hospital Medical Center, 735, 824, University of Iowa, 350; Kansas, Stormont-Vail Regional Medical Center, 103; Maryland, University of Maryland, 941, University of Maryland at Baltimore, 945, Washington County Hospital Association, 827; Massachusetts, Massachusetts College of Pharmacy and Allied Health Sciences, 726, 942, Medical Decision Resources, Inc., 726, Veterans Administration Medical Center, 948; Michigan, Midland Hospital Center, 186, Munson Medical Center, 186, University of Michigan, 945, Wayne State University, 1046; Missouri, Marion Laboratories, Inc., 631, Research Medical Center, 349, University of Missouri-Kansas City, 270; Nebraska, University of Nebraska Medical Center, 726; New Jersey, Advanced Therapeutics Communications International, 437, 519, 627, East Orange VA Medical Center, 731, Hoechst-Roussel Pharmaceuticals, 730, 827, 945, Rutgers—The State University of New Jersey, 827, 830, 948, Rutgers—The State University of New Jersey and Monmouth Medical Center, 631, Schering-Plough Corporation, 187, 942, Scientific Therapeutics Information, Inc., 518, 1047; New Mexico, Las Vegas Medical Center, 821; New York, HIP of New York, 730, Memorial Sloan-Kettering Cancer Center, 519, St. John's University, 102, State University of New York at Buffalo, 948, 1047; North Carolina, Glaxo Inc., 944, Wake Forest University, 187; North Dakota, North Dakota State University, 824; Ohio, Kendle Research Associates, 631, Miami Valley Hospital, 438, 734, The Toledo Hospital, 824, University Hospitals of Cleveland/Case Western Reserve University, 629; Oregon, Oregon State University, 438; Pennsylvania, Duquesne University, 103, 730, Pharmacists for Life, 735, 890, St. Francis Medical Center, 731, Temple University, 348, 731, University of Pittsburgh, 821; Saudi Arabia, King Faisal Specialist Hospital and Research Center, 439, 627; Tennessee, Beecham Laboratories, 348, 628; Texas, Brackenridge Hospital and University of Texas, 629, High Plains Baptist Hospital, 630, 726, HPI Health Care Services, 349, Scott & White Hospital, 349, University of Texas, 518, 630, University of Texas at Austin, 102; Utah, University of Utah Health Sciences Center, 728; Washington, DC, Greater Southeast Community Hospital, 349, 628; West Virginia, West Virginia University, 941, 1047, West Virginia University Health Sciences Center, 103, 185, 630; Wisconsin, University of Wisconsin-Madison, 185, 944, 1047; Wyoming, University of Wyoming, 629
 Pfizer Laboratories Division, Osmol pump, btw 728-729
 Roerig, Unasyn, 52, 148, 189, 232, 254, 312, 343, 396, 436, 480, 576, 684, 784, 888, 1110

Sandoz Pharmaceuticals, Sandostat, btw 104-ibc, btw 272-ibc, btw 440-ibc, btw 720-721, 933
 SIMKIN, Inc., The SIMKIN Pharmacokinetics System, 25, 136, 209, 289, 385, 464, 537, 1013
 SmithKline Beckman Company, Energix-B, 905, 991
 Therapeutic Software, Inc., Therapeutic Software, 362, 890

INDEX ABBREVIATIONS

A: Article
 CC: Critical Care Therapeutics
 CR: Pharmacotherapy Case Reports
 CS: Clinical Statistics
 cr: center insert
 DIAS: Drug Information Analysis Service
 DIR: Drug Interactions and Reactions Update
 DSP: Drug Selection Perspectives
 E: Editorial
 ET: Education and Training
 FF: Formulary Forum
 G: Geriatrics and Gerontology
 ibc: inside back cover
 ID: Investigational Drug Information
 ifc: inside front cover
 IR: International Reports
 L: Letters
 NC: News and Comments
 O: An Opinion
 obc: outside back cover
 PEC: Pharmacoeconomics
 PED: Pediatrics
 PEP: Pharmacoeconomics
 RPR: Research/Practice Reports
 SR: Short Reports
 TC: Therapeutic Controversies
 TM: Therapeutic Monitoring

Statement of ownership, management, and monthly circulation (12 issues, \$95 annually) of *DICI, The Annals of Pharmacotherapy*, publication no. 10429611. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, P.O. Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies each issue from October 88 to September 89 and no. of copies of September 89: A. total no. copies printed (net press run) 8772, 9000. B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 6174, 6115; C. total paid circulation 6174, 6115; D. free distribution 1360, 1600; E. total distribution (C+D) 7269, 7715; F. office use, left over, etc. 1238, 1285; G. total (E+F) 8772, 9000. No. of issues published annually: 12. Date of filing: 1 October 1989. Signed: Harvey A.K. Whitney, Jr., Publisher.

Moving? Send new address and mailing label to:

DICI, The Annals of Pharmacotherapy
 P.O. Box 42696, Cincinnati, OH 45242 USA

Name _____
 Address _____
 City _____
 State/Ctry. _____ ZIP _____
 Date change is effective (allow 6 wks.) _____

Affix old mailing label here

